US20120183523A1 - Methods and Compounds for Promoting Vessel Regression - Google Patents
Methods and Compounds for Promoting Vessel Regression Download PDFInfo
- Publication number
- US20120183523A1 US20120183523A1 US13/295,834 US201113295834A US2012183523A1 US 20120183523 A1 US20120183523 A1 US 20120183523A1 US 201113295834 A US201113295834 A US 201113295834A US 2012183523 A1 US2012183523 A1 US 2012183523A1
- Authority
- US
- United States
- Prior art keywords
- protein
- neovascularization
- disorder
- alk1
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 96
- 150000001875 compounds Chemical class 0.000 title claims description 61
- 230000001737 promoting effect Effects 0.000 title description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 77
- 206010029113 Neovascularisation Diseases 0.000 claims abstract description 48
- 239000000203 mixture Substances 0.000 claims abstract description 42
- 208000035475 disorder Diseases 0.000 claims description 66
- 230000014509 gene expression Effects 0.000 claims description 65
- 102100034136 Serine/threonine-protein kinase receptor R3 Human genes 0.000 claims description 63
- 101710082813 Serine/threonine-protein kinase receptor R3 Proteins 0.000 claims description 62
- 102000039446 nucleic acids Human genes 0.000 claims description 55
- 108020004707 nucleic acids Proteins 0.000 claims description 55
- 150000007523 nucleic acids Chemical class 0.000 claims description 55
- 210000001508 eye Anatomy 0.000 claims description 38
- 238000011282 treatment Methods 0.000 claims description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 25
- 238000012360 testing method Methods 0.000 claims description 25
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 24
- 238000011161 development Methods 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- 230000001225 therapeutic effect Effects 0.000 claims description 21
- 239000002773 nucleotide Substances 0.000 claims description 17
- 125000003729 nucleotide group Chemical group 0.000 claims description 17
- 229920001184 polypeptide Polymers 0.000 claims description 17
- 210000004204 blood vessel Anatomy 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 238000002347 injection Methods 0.000 claims description 15
- 239000007924 injection Substances 0.000 claims description 15
- 230000002792 vascular Effects 0.000 claims description 15
- 210000004087 cornea Anatomy 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 10
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 9
- 238000010171 animal model Methods 0.000 claims description 9
- 210000001525 retina Anatomy 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 208000010412 Glaucoma Diseases 0.000 claims description 6
- 206010065630 Iris neovascularisation Diseases 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 206010055665 Corneal neovascularisation Diseases 0.000 claims description 5
- 206010052428 Wound Diseases 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 5
- 201000000159 corneal neovascularization Diseases 0.000 claims description 5
- 210000000554 iris Anatomy 0.000 claims description 5
- 208000002780 macular degeneration Diseases 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 claims description 5
- 230000002207 retinal effect Effects 0.000 claims description 5
- 208000004413 Eyelid Neoplasms Diseases 0.000 claims description 4
- 206010050497 Eyelid tumour Diseases 0.000 claims description 4
- 210000000795 conjunctiva Anatomy 0.000 claims description 4
- 208000024519 eye neoplasm Diseases 0.000 claims description 4
- 201000008106 ocular cancer Diseases 0.000 claims description 4
- 208000025303 orbit neoplasm Diseases 0.000 claims description 4
- 201000000890 orbital cancer Diseases 0.000 claims description 4
- 210000001745 uvea Anatomy 0.000 claims description 4
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 claims description 3
- 206010011017 Corneal graft rejection Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 208000023715 Ocular surface disease Diseases 0.000 claims description 3
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims description 3
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims description 3
- 210000000744 eyelid Anatomy 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 206010023332 keratitis Diseases 0.000 claims description 3
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 3
- 208000015200 ocular cicatricial pemphigoid Diseases 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 210000003754 fetus Anatomy 0.000 claims description 2
- 210000004279 orbit Anatomy 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 282
- 102000004169 proteins and genes Human genes 0.000 description 242
- 235000018102 proteins Nutrition 0.000 description 212
- 239000000499 gel Substances 0.000 description 59
- 239000002299 complementary DNA Substances 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 44
- 241000699666 Mus <mouse, genus> Species 0.000 description 38
- 239000000047 product Substances 0.000 description 26
- 239000008188 pellet Substances 0.000 description 22
- 230000018109 developmental process Effects 0.000 description 21
- 108020004459 Small interfering RNA Proteins 0.000 description 20
- 230000000692 anti-sense effect Effects 0.000 description 19
- 108020003175 receptors Proteins 0.000 description 19
- 102000005962 receptors Human genes 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 239000004055 small Interfering RNA Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 238000004949 mass spectrometry Methods 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 11
- 239000002243 precursor Substances 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 150000003384 small molecules Chemical class 0.000 description 11
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 10
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 108090000994 Catalytic RNA Proteins 0.000 description 9
- -1 coatings Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 102000053642 Catalytic RNA Human genes 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 8
- 108091061960 Naked DNA Proteins 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 108091092562 ribozyme Proteins 0.000 description 8
- 230000035939 shock Effects 0.000 description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000000132 electrospray ionisation Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 238000000575 proteomic method Methods 0.000 description 7
- 108010048623 Collagen Receptors Proteins 0.000 description 6
- 101000591312 Homo sapiens Putative MORF4 family-associated protein 1-like protein UPP Proteins 0.000 description 6
- 102000000507 Integrin alpha2 Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102100034096 Putative MORF4 family-associated protein 1-like protein UPP Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 230000000750 progressive effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102100032197 Alpha-crystallin A chain Human genes 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- 101000799194 Homo sapiens Serine/threonine-protein kinase receptor R3 Proteins 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 108091030071 RNAI Proteins 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000009368 gene silencing by RNA Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102100029334 Beta-crystallin A3 Human genes 0.000 description 4
- 102100030504 Beta-crystallin A4 Human genes 0.000 description 4
- 102100027984 Beta-crystallin B3 Human genes 0.000 description 4
- 101150070265 CRYBB1 gene Proteins 0.000 description 4
- 102000005600 Cathepsins Human genes 0.000 description 4
- 108010084457 Cathepsins Proteins 0.000 description 4
- 102000004360 Cofilin 1 Human genes 0.000 description 4
- 108090000996 Cofilin 1 Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 101000919139 Homo sapiens Beta-crystallin A3 Proteins 0.000 description 4
- 101000919530 Homo sapiens Beta-crystallin A4 Proteins 0.000 description 4
- 101000859442 Homo sapiens Beta-crystallin B3 Proteins 0.000 description 4
- 201000003043 Persistent hyperplastic primary vitreous Diseases 0.000 description 4
- 108090000709 Phakinin Proteins 0.000 description 4
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 4
- 238000010847 SEQUEST Methods 0.000 description 4
- 102000037054 SLC-Transporter Human genes 0.000 description 4
- 108091006207 SLC-Transporter Proteins 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 108010002849 drebrins Proteins 0.000 description 4
- 238000001476 gene delivery Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 102000047644 human ACVRL1 Human genes 0.000 description 4
- 230000003463 hyperproliferative effect Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000001155 isoelectric focusing Methods 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000000751 protein extraction Methods 0.000 description 4
- 239000012723 sample buffer Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000009897 systematic effect Effects 0.000 description 4
- 238000004885 tandem mass spectrometry Methods 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 101150000418 ALK1 gene Proteins 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 101710150365 Albumin-1 Proteins 0.000 description 3
- 102100038910 Alpha-enolase Human genes 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 102100029335 Beta-crystallin A2 Human genes 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108091033380 Coding strand Proteins 0.000 description 3
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 3
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102100030421 Fatty acid-binding protein 5 Human genes 0.000 description 3
- 101710083187 Fatty acid-binding protein 5 Proteins 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 102100032518 Gamma-crystallin B Human genes 0.000 description 3
- 102100027813 Gamma-crystallin C Human genes 0.000 description 3
- 102100027812 Gamma-crystallin D Human genes 0.000 description 3
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 3
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 3
- 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000920937 Homo sapiens Alpha-crystallin A chain Proteins 0.000 description 3
- 101000919133 Homo sapiens Beta-crystallin A2 Proteins 0.000 description 3
- 101000942158 Homo sapiens Gamma-crystallin B Proteins 0.000 description 3
- 101000859938 Homo sapiens Gamma-crystallin C Proteins 0.000 description 3
- 101000859943 Homo sapiens Gamma-crystallin D Proteins 0.000 description 3
- 108010017642 Integrin alpha2beta1 Proteins 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 102000004246 Phakinin Human genes 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 108010026552 Proteome Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 3
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 3
- 102000018690 Trypsinogen Human genes 0.000 description 3
- 108010027252 Trypsinogen Proteins 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 102100035071 Vimentin Human genes 0.000 description 3
- 108010065472 Vimentin Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 210000003484 anatomy Anatomy 0.000 description 3
- 239000000074 antisense oligonucleotide Substances 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 150000003906 phosphoinositides Chemical class 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002731 protein assay Methods 0.000 description 3
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000006711 vascular endothelial growth factor production Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 210000005048 vimentin Anatomy 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 230000036266 weeks of gestation Effects 0.000 description 3
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 2
- 102000004899 14-3-3 Proteins Human genes 0.000 description 2
- 101710112812 14-3-3 protein Proteins 0.000 description 2
- 101710108995 14-3-3 protein theta Proteins 0.000 description 2
- 102100027831 14-3-3 protein theta Human genes 0.000 description 2
- UTSXERRKRAEDOV-UHFFFAOYSA-N 3-[dimethyl-[3-(tetradecanoylamino)propyl]azaniumyl]propane-1-sulfonate Chemical compound CCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O UTSXERRKRAEDOV-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 2
- 101150060623 Acvrl1 gene Proteins 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108010058060 Alanine-tRNA ligase Proteins 0.000 description 2
- 102100037399 Alanine-tRNA ligase, cytoplasmic Human genes 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- 102100033899 Ankyrin repeat and SOCS box protein 14 Human genes 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 108010077173 BB Form Creatine Kinase Proteins 0.000 description 2
- 102100029388 Beta-crystallin B2 Human genes 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 101001016210 Bos taurus Dynein axonemal heavy chain 12 Proteins 0.000 description 2
- 108010059108 CD18 Antigens Proteins 0.000 description 2
- 101150063057 CRYAB gene Proteins 0.000 description 2
- 102000000584 Calmodulin Human genes 0.000 description 2
- 108010041952 Calmodulin Proteins 0.000 description 2
- 102100021868 Calnexin Human genes 0.000 description 2
- 108010056891 Calnexin Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000003908 Cathepsin D Human genes 0.000 description 2
- 108090000258 Cathepsin D Proteins 0.000 description 2
- 102100022785 Creatine kinase B-type Human genes 0.000 description 2
- 102100039116 DNA repair protein RAD50 Human genes 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 102100028952 Drebrin Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 102100039326 Gamma-crystallin S Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102100031000 Hepatoma-derived growth factor Human genes 0.000 description 2
- 101000925508 Homo sapiens Ankyrin repeat and SOCS box protein 14 Proteins 0.000 description 2
- 101000743929 Homo sapiens DNA repair protein RAD50 Proteins 0.000 description 2
- 101000838600 Homo sapiens Drebrin Proteins 0.000 description 2
- 101000745467 Homo sapiens Gamma-crystallin S Proteins 0.000 description 2
- 101000800847 Homo sapiens Protein TFG Proteins 0.000 description 2
- 101000628899 Homo sapiens Small ubiquitin-related modifier 1 Proteins 0.000 description 2
- 101000788607 Homo sapiens Tubulin alpha-3C chain Proteins 0.000 description 2
- 101000625727 Homo sapiens Tubulin beta chain Proteins 0.000 description 2
- 101000788517 Homo sapiens Tubulin beta-2A chain Proteins 0.000 description 2
- 101000713575 Homo sapiens Tubulin beta-3 chain Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 101150059675 LMNB1 gene Proteins 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 102100027454 Laminin subunit beta-2 Human genes 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 206010024214 Lenticular opacities Diseases 0.000 description 2
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 2
- 101710084185 Leucine-rich repeat-containing protein 4C Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102000001696 Mannosidases Human genes 0.000 description 2
- 108010054377 Mannosidases Proteins 0.000 description 2
- 108090000143 Mouse Proteins Proteins 0.000 description 2
- 108091092724 Noncoding DNA Proteins 0.000 description 2
- 102000012547 Olfactory receptors Human genes 0.000 description 2
- 108050002069 Olfactory receptors Proteins 0.000 description 2
- 102000000470 PDZ domains Human genes 0.000 description 2
- 108050008994 PDZ domains Proteins 0.000 description 2
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000007982 Phosphoproteins Human genes 0.000 description 2
- 108010089430 Phosphoproteins Proteins 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 102000011195 Profilin Human genes 0.000 description 2
- 108050001408 Profilin Proteins 0.000 description 2
- 102100037686 Protein SSX2 Human genes 0.000 description 2
- 101710149284 Protein SSX2 Proteins 0.000 description 2
- 102100033661 Protein TFG Human genes 0.000 description 2
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 2
- 102000015176 Proton-Translocating ATPases Human genes 0.000 description 2
- 108010039518 Proton-Translocating ATPases Proteins 0.000 description 2
- 102100026940 Small ubiquitin-related modifier 1 Human genes 0.000 description 2
- 102100028806 Striatin-4 Human genes 0.000 description 2
- 102000043168 TGF-beta family Human genes 0.000 description 2
- 108091085018 TGF-beta family Proteins 0.000 description 2
- 102100033082 TNF receptor-associated factor 3 Human genes 0.000 description 2
- 108090000922 TNF receptor-associated factor 3 Proteins 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 102100026145 Transitional endoplasmic reticulum ATPase Human genes 0.000 description 2
- 108010023649 Tripartite Motif Proteins Proteins 0.000 description 2
- 102000011408 Tripartite Motif Proteins Human genes 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102100025235 Tubulin alpha-3C chain Human genes 0.000 description 2
- 102100024717 Tubulin beta chain Human genes 0.000 description 2
- 102100025225 Tubulin beta-2A chain Human genes 0.000 description 2
- 102100036790 Tubulin beta-3 chain Human genes 0.000 description 2
- 108010027273 Valosin Containing Protein Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 108010055905 alpha-Crystallin A Chain Proteins 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 108010087889 beta-crystallin B2 Proteins 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960004424 carbon dioxide Drugs 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000004240 ciliary body Anatomy 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 201000000787 conjunctival cancer Diseases 0.000 description 2
- 208000017903 conjunctival tumor Diseases 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 108010052188 hepatoma-derived growth factor Proteins 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
- 238000000534 ion trap mass spectrometry Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 108010028309 kalinin Proteins 0.000 description 2
- 108010009114 laminin beta2 Proteins 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000007425 progressive decline Effects 0.000 description 2
- 230000001179 pupillary effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000790 retinal pigment Substances 0.000 description 2
- 210000001210 retinal vessel Anatomy 0.000 description 2
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229960004291 sucralfate Drugs 0.000 description 2
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000006459 vascular development Effects 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
- MDLAAYDRRZXJIF-UHFFFAOYSA-N 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-4-piperidinol Chemical compound C1CC(O)(C=2C=C(C(Cl)=CC=2)C(F)(F)F)CCN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 MDLAAYDRRZXJIF-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 102000000454 14-3-3 protein sigma Human genes 0.000 description 1
- 108050008974 14-3-3 protein sigma Proteins 0.000 description 1
- YHPKGSLWSUCJQK-UHFFFAOYSA-N 2-[[2-[[2-[[2-[[2-[[2-[[5-amino-2-[[2-[(2,4-diamino-4-oxobutanoyl)amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-carboxypropanoyl]amino]-5-(diaminomethylideneamino) Chemical compound NC(N)=NCCCC(C(=O)NC(C(C)C)C(O)=O)NC(=O)C(CC(O)=O)NC(=O)C(CCSC)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(N)CC(N)=O YHPKGSLWSUCJQK-UHFFFAOYSA-N 0.000 description 1
- GXIURPTVHJPJLF-UWTATZPHSA-N 2-phospho-D-glyceric acid Chemical compound OC[C@H](C(O)=O)OP(O)(O)=O GXIURPTVHJPJLF-UWTATZPHSA-N 0.000 description 1
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 102100023912 40S ribosomal protein S12 Human genes 0.000 description 1
- 102100021546 60S ribosomal protein L10 Human genes 0.000 description 1
- 101710187296 60S ribosomal protein L10 Proteins 0.000 description 1
- 102100023777 60S ribosomal protein L31 Human genes 0.000 description 1
- 108091022885 ADAM Proteins 0.000 description 1
- 101150100983 Acsl6 gene Proteins 0.000 description 1
- 101710093498 Actin, gamma Proteins 0.000 description 1
- 102100034070 Actin-like protein 6B Human genes 0.000 description 1
- 102100028100 Activating signal cointegrator 1 Human genes 0.000 description 1
- 101710089542 Activating signal cointegrator 1 Proteins 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 101150045885 Acvr1 gene Proteins 0.000 description 1
- 108010045938 Adaptor Protein Complex gamma Subunits Proteins 0.000 description 1
- 102100030446 Adenosine 5'-monophosphoramidase HINT1 Human genes 0.000 description 1
- 101710165425 Alpha-enolase Proteins 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 101710165534 Ankyrin homolog Proteins 0.000 description 1
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
- 102000008095 Arylalkylamine N-Acetyltransferase Human genes 0.000 description 1
- 108010074515 Arylalkylamine N-Acetyltransferase Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241001598984 Bromius obscurus Species 0.000 description 1
- 101150093222 CTTN gene Proteins 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 102100021629 Calcium-binding protein 39-like Human genes 0.000 description 1
- 101710093032 Calcium-binding protein 39-like Proteins 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 102100033379 Carbohydrate sulfotransferase 14 Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000499489 Castor canadensis Species 0.000 description 1
- 208000003163 Cavernous Hemangioma Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 101710104955 Cell division control protein 25 Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000016623 Choroid neoplasm Diseases 0.000 description 1
- 206010070957 Choroidal haemangioma Diseases 0.000 description 1
- 206010008786 Choroidal haemorrhage Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 208000032972 Conjunctival malignant melanoma Diseases 0.000 description 1
- 206010066384 Conjunctival melanoma Diseases 0.000 description 1
- 206010066925 Conjunctival primary acquired melanosis Diseases 0.000 description 1
- 206010072143 Conjunctival telangiectasia Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 101710101548 Cytochrome P450 2D9 Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 101100412663 Danio rerio rasgef1bb gene Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 101800001224 Disintegrin Proteins 0.000 description 1
- 102100031636 Dynein axonemal heavy chain 9 Human genes 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102100034893 E3 ubiquitin-protein ligase HUWE1 Human genes 0.000 description 1
- 102100024816 E3 ubiquitin-protein ligase TRAF7 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 206010051045 Eye naevus Diseases 0.000 description 1
- 108010066805 F-Box Proteins Proteins 0.000 description 1
- 102000018700 F-Box Proteins Human genes 0.000 description 1
- 101150024944 FBXO9 gene Proteins 0.000 description 1
- 102100036123 Far upstream element-binding protein 2 Human genes 0.000 description 1
- 101710133942 Far upstream element-binding protein 2 Proteins 0.000 description 1
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 1
- 101000941893 Felis catus Leucine-rich repeat and calponin homology domain-containing protein 1 Proteins 0.000 description 1
- 102100031509 Fibrillin-1 Human genes 0.000 description 1
- 108010030229 Fibrillin-1 Proteins 0.000 description 1
- 102000012548 Fibroblast growth factor 22 Human genes 0.000 description 1
- 108050002062 Fibroblast growth factor 22 Proteins 0.000 description 1
- 102100027625 Fibrous sheath-interacting protein 2 Human genes 0.000 description 1
- 101710107040 Fibrous sheath-interacting protein 2 Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000034286 G proteins Human genes 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 102100039331 Gamma-crystallin A Human genes 0.000 description 1
- 102100032136 Gamma-crystallin N Human genes 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000867289 Glycine max Hsp70-Hsp90 organizing protein 1 Proteins 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 102100033067 Growth factor receptor-bound protein 2 Human genes 0.000 description 1
- 101150096895 HSPB1 gene Proteins 0.000 description 1
- 102100027421 Heat shock cognate 71 kDa protein Human genes 0.000 description 1
- 101710104933 Heat shock cognate 71 kDa protein Proteins 0.000 description 1
- 102100032510 Heat shock protein HSP 90-beta Human genes 0.000 description 1
- 101710163596 Heat shock protein HSP 90-beta Proteins 0.000 description 1
- 102100028909 Heterogeneous nuclear ribonucleoprotein K Human genes 0.000 description 1
- 108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 description 1
- 101710195459 Histidine triad nucleotide-binding protein Proteins 0.000 description 1
- 101150022267 Hnrnpk gene Proteins 0.000 description 1
- 101000798876 Homo sapiens Actin-like protein 6B Proteins 0.000 description 1
- 101000866325 Homo sapiens Dynein axonemal heavy chain 9 Proteins 0.000 description 1
- 101001019732 Homo sapiens E3 ubiquitin-protein ligase HUWE1 Proteins 0.000 description 1
- 101000830899 Homo sapiens E3 ubiquitin-protein ligase TRAF7 Proteins 0.000 description 1
- 101000745534 Homo sapiens Gamma-crystallin A Proteins 0.000 description 1
- 101000921118 Homo sapiens Gamma-crystallin N Proteins 0.000 description 1
- 101000590482 Homo sapiens Kinetochore protein Nuf2 Proteins 0.000 description 1
- 101001023271 Homo sapiens Laminin subunit gamma-2 Proteins 0.000 description 1
- 101001001294 Homo sapiens Lysosomal acid phosphatase Proteins 0.000 description 1
- 101000630572 Homo sapiens Molybdopterin-synthase sulfurtransferase Proteins 0.000 description 1
- 101000968663 Homo sapiens MutS protein homolog 5 Proteins 0.000 description 1
- 101001072202 Homo sapiens Protein disulfide-isomerase Proteins 0.000 description 1
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 description 1
- 101000862167 Homo sapiens Putative F-box/LRR-repeat protein 21 Proteins 0.000 description 1
- 101000589631 Homo sapiens Putative N-acetyltransferase 8B Proteins 0.000 description 1
- 101000713557 Homo sapiens Tubulin alpha chain-like 3 Proteins 0.000 description 1
- 101000838456 Homo sapiens Tubulin alpha-1B chain Proteins 0.000 description 1
- 101000838350 Homo sapiens Tubulin alpha-1C chain Proteins 0.000 description 1
- 101000713585 Homo sapiens Tubulin beta-4A chain Proteins 0.000 description 1
- 101000873780 Homo sapiens m7GpppN-mRNA hydrolase Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 102000004867 Hydro-Lyases Human genes 0.000 description 1
- 108090001042 Hydro-Lyases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 description 1
- 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 description 1
- 102100026818 Inhibin beta E chain Human genes 0.000 description 1
- 102100039872 Inner centromere protein Human genes 0.000 description 1
- 101710162819 Inner centromere protein Proteins 0.000 description 1
- 102000000426 Integrin alpha6 Human genes 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010073086 Iris melanoma Diseases 0.000 description 1
- 206010057412 Iris neoplasm Diseases 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 101710059433 KIAA1755 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 102100025756 Keratin, type II cytoskeletal 5 Human genes 0.000 description 1
- 108010070553 Keratin-5 Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 102100032431 Kinetochore protein Nuf2 Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100035159 Laminin subunit gamma-2 Human genes 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 102100022187 Leucine-rich repeat-containing protein 4C Human genes 0.000 description 1
- 206010025219 Lymphangioma Diseases 0.000 description 1
- 102100035699 Lysosomal acid phosphatase Human genes 0.000 description 1
- 102100032515 Male-specific lethal 3 homolog Human genes 0.000 description 1
- 108050002866 Male-specific lethal 3 homolog Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 235000011779 Menyanthes trifoliata Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102100026101 Molybdopterin-synthase sulfurtransferase Human genes 0.000 description 1
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 1
- 102100030610 Mothers against decapentaplegic homolog 5 Human genes 0.000 description 1
- 101710143113 Mothers against decapentaplegic homolog 5 Proteins 0.000 description 1
- 208000003423 Mucocele Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101000812646 Mus musculus Endoplasmin Proteins 0.000 description 1
- 101000862168 Mus musculus F-box/LRR-repeat protein 21 Proteins 0.000 description 1
- 101001062856 Mus musculus Fatty acid-binding protein 5 Proteins 0.000 description 1
- 101100453307 Mus musculus Krt15 gene Proteins 0.000 description 1
- 102100021156 MutS protein homolog 5 Human genes 0.000 description 1
- 101150054880 NASP gene Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 102100023904 Nuclear autoantigenic sperm protein Human genes 0.000 description 1
- 101710149564 Nuclear autoantigenic sperm protein Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 101710194730 Oogenesin-1 Proteins 0.000 description 1
- 208000007792 Orbital Pseudotumor Diseases 0.000 description 1
- 208000035452 Orbital pseudotumour Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000016774 Otoferlin Human genes 0.000 description 1
- 108050006335 Otoferlin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101000785215 Papaver somniferum (13S,14R)-1,13-dihydroxy-N-methylcanadine 13-O-acetyltransferase AT1 Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 102100035832 Phakinin Human genes 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100030264 Pleckstrin Human genes 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 101800001092 Protein 3B Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000005569 Protein Phosphatase 1 Human genes 0.000 description 1
- 108010059000 Protein Phosphatase 1 Proteins 0.000 description 1
- 102000006478 Protein Phosphatase 2 Human genes 0.000 description 1
- 108010058956 Protein Phosphatase 2 Proteins 0.000 description 1
- 102100036352 Protein disulfide-isomerase Human genes 0.000 description 1
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 1
- 102100027753 Putative F-box/LRR-repeat protein 21 Human genes 0.000 description 1
- 102100032379 Putative N-acetyltransferase 8B Human genes 0.000 description 1
- 102100034576 Quinone oxidoreductase Human genes 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 208000034541 Rare lymphatic malformation Diseases 0.000 description 1
- 102000003901 Ras GTPase-activating proteins Human genes 0.000 description 1
- 108090000231 Ras GTPase-activating proteins Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100032445 Relaxin receptor 2 Human genes 0.000 description 1
- 101710095753 Relaxin receptor 2 Proteins 0.000 description 1
- 101710088839 Replication initiation protein Proteins 0.000 description 1
- 206010038824 Retinal arteriovenous malformation Diseases 0.000 description 1
- 208000016624 Retinal neoplasm Diseases 0.000 description 1
- 206010038899 Retinal telangiectasia Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 108090000180 Ribosomal protein L31 Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000000341 S-Phase Kinase-Associated Proteins Human genes 0.000 description 1
- 108010055623 S-Phase Kinase-Associated Proteins Proteins 0.000 description 1
- 108050007572 S-phase kinase-associated protein 1 Proteins 0.000 description 1
- 102000033686 SH3 domain binding proteins Human genes 0.000 description 1
- 108091009674 SH3 domain binding proteins Proteins 0.000 description 1
- 102000000395 SH3 domains Human genes 0.000 description 1
- 108050008861 SH3 domains Proteins 0.000 description 1
- 101700032040 SMAD1 Proteins 0.000 description 1
- 101700031501 SMAD9 Proteins 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 102000009203 Sema domains Human genes 0.000 description 1
- 108050000099 Sema domains Proteins 0.000 description 1
- 102100027068 Septin-11 Human genes 0.000 description 1
- 101710005686 Septin-11 Proteins 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102000049870 Smad8 Human genes 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100025292 Stress-induced-phosphoprotein 1 Human genes 0.000 description 1
- 101710140918 Stress-induced-phosphoprotein 1 Proteins 0.000 description 1
- 101710106072 Striatin-4 Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 102100036771 T-box transcription factor TBX1 Human genes 0.000 description 1
- 101710167705 T-box transcription factor TBX1 Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 101150050957 TNKS gene Proteins 0.000 description 1
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 1
- 101710173511 Tensin homolog Proteins 0.000 description 1
- 241000223892 Tetrahymena Species 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 101710199480 Titin homolog Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100033632 Tropomyosin alpha-1 chain Human genes 0.000 description 1
- 101710128188 Tropomyosin alpha-1 chain Proteins 0.000 description 1
- 102100033080 Tropomyosin alpha-3 chain Human genes 0.000 description 1
- 101710091952 Tropomyosin alpha-3 chain Proteins 0.000 description 1
- 101710186379 Tropomyosin-1 Proteins 0.000 description 1
- 102100036795 Tubulin alpha chain-like 3 Human genes 0.000 description 1
- 102100028969 Tubulin alpha-1B chain Human genes 0.000 description 1
- 102100028985 Tubulin alpha-1C chain Human genes 0.000 description 1
- 102100036788 Tubulin beta-4A chain Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108091026822 U6 spliceosomal RNA Proteins 0.000 description 1
- 101710173440 Ubiquilin-2 Proteins 0.000 description 1
- 102100039933 Ubiquilin-2 Human genes 0.000 description 1
- 102100023341 Ubiquitin-40S ribosomal protein S27a Human genes 0.000 description 1
- 102000018390 Ubiquitin-Specific Proteases Human genes 0.000 description 1
- 108010066496 Ubiquitin-Specific Proteases Proteins 0.000 description 1
- 102100022856 Uncharacterized protein KIAA1755 Human genes 0.000 description 1
- 102000008219 Uncoupling Protein 2 Human genes 0.000 description 1
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 101800003106 VPg Proteins 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 206010047050 Vascular anomaly Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 101800001133 Viral protein genome-linked Proteins 0.000 description 1
- 208000013058 Weber syndrome Diseases 0.000 description 1
- 101000756604 Xenopus laevis Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101710145602 Zinc finger protein 120 Proteins 0.000 description 1
- 102100035849 Zinc finger protein 462 Human genes 0.000 description 1
- 101710143632 Zinc finger protein 462 Proteins 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 108010075843 alpha-2-HS-Glycoprotein Proteins 0.000 description 1
- 102000012005 alpha-2-HS-Glycoprotein Human genes 0.000 description 1
- 108010007908 alpha-Crystallins Proteins 0.000 description 1
- 102000007362 alpha-Crystallins Human genes 0.000 description 1
- 102000019199 alpha-Mannosidase Human genes 0.000 description 1
- 108010012864 alpha-Mannosidase Proteins 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000005744 arteriovenous malformation Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000027439 benign eyelid neoplasm Diseases 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000007293 brain stem infarction Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 201000002588 choroid cancer Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000003683 corneal stroma Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 108010041331 dermatan-4-sulfotransferase-1 Proteins 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000005264 electron capture Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 208000017338 epidermoid cysts Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 206010015831 extraocular retinoblastoma Diseases 0.000 description 1
- 230000004373 eye development Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 208000026043 eyelid cancer Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 108091022862 fatty acid binding Proteins 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108010017007 glucose-regulated proteins Proteins 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- IUAYMJGZBVDSGL-XNNAEKOYSA-N gramicidin S Chemical compound C([C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(C)C)C(=O)N1)C(C)C)=O)CC(C)C)C(C)C)C1=CC=CC=C1 IUAYMJGZBVDSGL-XNNAEKOYSA-N 0.000 description 1
- 229950009774 gramicidin s Drugs 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 201000009314 lacrimal gland carcinoma Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004901 leucine-rich repeat Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 102100035860 m7GpppN-mRNA hydrolase Human genes 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000002576 malignant conjunctival melanoma Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000004942 nevus of Ota Diseases 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 208000027500 optic nerve neoplasm Diseases 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000010668 orbital plasma cell granuloma Diseases 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 102000005309 phosducin Human genes 0.000 description 1
- 108010031256 phosducin Proteins 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 108010026735 platelet protein P47 Proteins 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000007542 postnatal development Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 108010092841 ribosomal protein S12 Proteins 0.000 description 1
- 108010011179 ribosomal protein S27a Proteins 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 108010013318 zeta-Crystallins Proteins 0.000 description 1
- 108010064992 zinedin Proteins 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/164—Retinal disorders, e.g. retinopathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
Definitions
- This invention relates to methods and compounds for promoting vessel regression, e.g., to treat disorders associated with neovascularization.
- the first elements of the human hyaloid vasculature to undergo regression are the VHP, followed by the TVL, PM and lastly the main hyaloid trunk, commencing at 12 weeks of gestation (WG) and culminating in the involution of the entire hyaloid by 35-36 WG (Mann I. The Development of the Human Eye. Pp 201-32. Grune & Stratton Inc: New York, 1964).
- failure of the hyaloid vascular system to regress can lead to a condition known as persistent hyperplastic primary vitreous (PHPV), which can result in permanent blindness if left untreated.
- PPPV persistent hyperplastic primary vitreous
- mice the hyaloid vascular system is first recognized at embryonic day 10.5 (E10.5), is complete by E13.5 and regresses postnatally prior to eyelid opening (Mitchell C A, et al., Dev. Dyn. 213(3):322-33 (1998)).
- E10.5 embryonic day 10.5
- E13.5 embryonic day 13.5
- P16 post-gestational day 16
- the anti-angiogenic ability of the vitreous humor and vitreous extracts may also be important in the regression of the TVL (Preis et al., Am. J. Ophthalmol. 84 (3):323-8 (1977); Felton et al., Arch. Ophthalmol. 97 (9):1710-3 (1979); Lutty et al., Invest. Ophthalmol. Vis. Sci. 24 (1):52-6 (1983); Taylor and Weiss, Biochem Biophys Res Commun. 133 (3):911-6 (1985); Zhu et al., Aust. N. Z. J. Ophthalmol. 25 Suppl 1:S57-60 (1997); Ramesh et al., Br. J. Ophthalmol.
- Hyalocytes play also a role in the regression of the TVL (McMenamin et al., Invest. Ophthalmol. V is Sci. 43 (7):2076-82 (2002)).
- Lutty et al. have demonstrated that the hyalocytes produce and process transforming growth factor- ⁇ (TGF- ⁇ ) which may inhibit is the proliferation of the vascular endothelial cells in this system (Lutty et al., Invest. Ophthalmol. Vis. Sci. 34 (3):477-87 (1993)).
- TGF- ⁇ transforming growth factor- ⁇
- F fibroblast growth factor
- PDGF platelet-derived growth factor
- VEGF vascular endothelial growth factor
- the present invention is based, at least in part, on the results of proteomic analysis of the mouse lens and vitreous during postnatal development, which identified novel proteins that contribute to regression of the hyaloid system.
- two-dimensional electrophoresis and mass spectrometry of the developing mouse lens and vitreous identified activin receptor-like kinase-1 (ALK1) as a differentially expressed protein during HVS regression; immunohistochemical staining demonstrated the localization of ALK1 in the TVL; and overexpression of ALK1 in the cornea resulted in inhibition of bFGF-induced corneal neovascularization in vivo.
- ALK1 activin receptor-like kinase-1
- ALK1 polypeptides and nucleic acids are useful compositions and targets for treating disorders associated with neovascularization (NV), and in cancer therapy.
- the invention provides methods for treating patients who have a disorder associated with neovascularization, e.g., an ophthalmological disorder associated with neovascularization.
- the methods include administering to the patient a therapeutically effective amount of an ALK1 polypeptide or nucleic acid composition, e.g., as described herein.
- the invention further includes therapeutic compositions including the ALK1 polypeptides or nucleic acids described herein, as well as inhibitors and/or agonists thereof, and methods for identifying such compounds.
- Ophthalmological disorders associated with neovascularization include eye cancer, age-related macular degeneration, retinopathy of prematurity, corneal graft rejection, glaucoma, diabetic retinopathy, wounds, age-related macular degeneration, herpetic and infectious keratitis, ocular ischemia, neovascular glaucoma, corneal, uveal and iris neovascularization, orbital and eyelid tumors, Stevens Johnson Syndrome, ocular cicatricial pemphigoid, and ocular surface diseases.
- the ophthalmological disorder is associated with corneal, retinal, choroidal, uveal, or iris neovascularization.
- the administering can be, e.g., topical or parenteral administration into the eye, e.g., including, but not limited to, local injection into or near the cornea, retina, vitreous, uvea, orbit, eyelid, conjunctiva, or iris.
- the disorder is cancer, e.g., as described herein.
- the subject is selected on the basis that he or she has a disorder associated with neovascularization as described herein.
- the administering can be, e.g., local or systemic, e.g., parenteral or oral.
- the invention provides methods for identifying candidate therapeutic compounds for the treatment of a disorder associated with neovascularization.
- the methods include obtaining a sample including a cell that is capable of expressing one or more of the genes listed in Tables 1-6; contacting the sample with the test compound; and evaluating levels, expression, or activity of the gene(s) in the sample, e.g., in the cell. Modulation of levels, expression, or activity of the gene(s) in the sample indicates that the test compound is a candidate therapeutic compound for the treatment of a disorder associated with neovascularization.
- the levels, expression, or activity of the gene in the sample can be evaluated by methods known in the art, e.g., enzyme assays, immunoassays, high-throughput DNA, RNA, or protein assays, etc.
- the gene is ALK1.
- the method further includes administering the candidate therapeutic compound to an animal model of a disorder associated with neovascularization, and monitoring the animal model for an effect of the candidate therapeutic compound on a parameter of the disorder, e.g., vascularisation, in the animal.
- a candidate therapeutic compound that causes an improvement in the parameter in the animal model is a candidate therapeutic agent for the treatment of the disorder.
- the methods further include administering the candidate therapeutic agent to a subject having the disorder, e.g., a subject in a clinical trial, and monitoring a parameter of the disorder in the subject.
- a candidate therapeutic agent that improves the parameter in the subject is a therapeutic agent for the treatment of the disorder.
- the parameter is visual acuity.
- the methods include administering a therapeutically effective amount of the therapeutic agent to a subject in need of treatment for the disorder, thereby treating the disorder.
- the invention provides methods for identifying candidate compounds, e.g., naturally-occurring compounds, e.g., a polypeptide or biologically active fragment thereof, for the treatment of a disorder associated with neovascularization.
- candidate compounds e.g., naturally-occurring compounds, e.g., a polypeptide or biologically active fragment thereof.
- the methods include providing a sample including:
- the invention includes methods for treating a disorder associated with neovascularization, e.g., an ophthalmological disorder associated with neovascularization as described herein, in a subject by administering a therapeutically effective amount of a therapeutic composition including an activin receptor-like kinase-1 (ALK1) polynucleotide or polypeptide, or an active fragment thereof.
- a disorder associated with neovascularization e.g., an ophthalmological disorder associated with neovascularization as described herein
- a therapeutic composition including an activin receptor-like kinase-1 (ALK1) polynucleotide or polypeptide, or an active fragment thereof.
- ALK1 activin receptor-like kinase-1
- FIGS. 1A-C Proteomic analysis of proteins from the lens and vitreous of P1 and P16 mice.
- the merged image ( 1 A) represents the warped image between P1 ( 1 B) and P16 ( 1 C) obtained with Phoretix 2D evolution software.
- the proteins excised from 2-D gel (P16) for analysis and identification by mass spectrometry are identified with numbers 1-20 ( 1 C).
- FIGS. 2A-Q bFGF-pellet induced corneal neovascularization (NV) is inhibited by naked ALK1 DNA injection in vivo.
- No-pellet controls are shown in 3 A-H: Injection of naked DNA [ALK1 ( 2 E-H) and vector only ( 2 A-D)] did not induce corneal NV.
- the vector plus pellet positive controls are shown in 3 I-L: development of NV in the corneal stroma was evident by day 4 ( 2 J); new vessels continued to grow in the direction of the pellet on days 7 and 14. None of the mice in the ALK1 and pellet groups (2M-P) showed development of corneal NV on days 1, 4, 7, and 14 after pellet implantation.
- Asterisk (*) indicates pellet implantation.
- the area of corneal NV of the four groups at days 1-14 is shown ( 2 Q).
- FIG. 3A-B are the amino acid ( 3 A; SEQ ID NO:1) and nucleic acid ( 3 B; SEQ ID NO:2) sequences of human ALK1.
- Tables 1-6 list proteins which are expected to play a role in vascularisation, inhibition of blood vessel regression, both in the HVS and in other systems, e.g., including pathophysiological processes, and are thus useful in the treatment of disorders associated with neovascularization, as described herein.
- ALK1 Activin Receptor-Like Kinase-1
- TGF- ⁇ is a potent inhibitor of vascular endothelial cell proliferation (Lutty et al., (1993), supra). It regulates endothelial proliferation via two receptor/Smad (mother against decapentaplegic) pathways. After ligand binding and activation of Type I receptors, signals are transduced from the membrane to the nucleus via Smads (Seki et al., Circ Res 93, 682-689 (2003)). Type I receptors recruit and phosphorylate Smads, such as Smads2 and 3 by the T ⁇ RI/ALK5 type I receptor in response to TGF- ⁇ , and Smads1, 5 and 8 by the BMP (bone morphogenetic protein) type I receptors (Feng, Ann. Rev. Cell. Dev. Biol. 659-693 (2005)).
- ALK1 is one of the seven Type I receptors for the TGF- ⁇ family of proteins (ten Dijke et al., Science 264, 101-104 (1994); GenelD: 94; GenBank Accession Nos. NM — 000020.1 (nucleic acid) and NP — 000011.1 (polypeptide)).
- ALK1 expression has been detected in endothelial cells of highly vascularized tissues (lungs and placenta) (Panchenko et al., Am. J. Physiol. 270, L547-L558 (1996)), normal and neoplastic pituitary cells (Alexander et al., J. Clin. Endocrinol. Metab.
- ALK1 transduces the TGF- ⁇ 1 signal by phosphorylating Smad1, Smad5 or Smad8 (Goumans, et al., EMBO. J. 21, 1743-1753 (2002); Oh et al., Proc. Natl. Acad. Sci. U.S.A.
- ALK5 activates Smads2 and 3 which up-regulate VEGF production (Goumans et al., EMBO J. 21, 1743-1753 (2002)).
- Smad complexes Upon phosphorylation by the receptors, Smad complexes translocate into the nucleus, where they cooperate with sequence-specific transcription factors at the promoter DNA to regulate gene expression (Feng and Derynck, Annu Rev. Cell. Dev. Biol. 659-693 (2005)). This functional and physical interaction confer both specificity and complexity in transcriptional responses to TGF- ⁇ family ligands (Id.).
- HHT Hereditary Hemorrhagic Telangiectasia
- This is an autosomal-dominant disorder, also known as Osler-Rendu-Weber syndrome, characterized by the age-dependent development of focal arteriovenous malformations and telangiectases (Srinivasan et al., Hum. Mol. Genet. 12, 473-482 (2003)).
- HHT type 2 is caused by loss of function of the activin receptor-like kinase 1 (ACVRL1 or ALK1) (Id.).
- ACVRL1 or ALK1 activin receptor-like kinase 1
- the disease is characterized by dilated, thin-walled, vascular anomalies of the skin and mucous membranes and recurrent epistaxis.
- abnormal eye disorders have been documented in 45-65% of patients with HHT, with the most common lesions being conjunctival telangiectasias (Brant et al., Am. J. Ophthalmol. 107, 642-646 (1989); Vase and Vase, Acta. Ophthalmol. Copen. 57, 1084-1090 (1979)).
- Active fragments thereof include, e.g., amino acids 22-503 of SEQ ID NO:1, or nucleotides 346-1791 of SEQ ID NO:2. Active fragments can also include the GS motif, i.e., amino acids 173-202 of SEQ ID NO:1; the Serine/Threonine protein kinases, catalytic domain, i.e., amino acids 204-487 of SEQ ID NO:1; and/or the Activin types I and II receptor domain, i.e., amino acids 19-103 of SEQ ID NO:1.
- An active fragment retains the ability to block bFGF-induced neovascularization.
- Homologs of the human ALK1 in other species are known, e.g., for rat, GenBank Accession No. NM — 022441.1; for mouse, NM — 009612.1
- the polypeptides listed in Tables 1-6, and nucleic acid molecules encoding or inhibiting them, can be incorporated into pharmaceutical compositions as active ingredients.
- the pharmaceutical compositions include a human ALK1 polypeptide (e.g., SEQ ID NO:1) or polynucleotide (e.g., SEQ ID NO:2), or an active fragment thereof.
- SEQ ID NO:1 human ALK1 polypeptide
- polynucleotide e.g., SEQ ID NO:2
- compositions typically include the active ingredient and a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier includes saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds can also be incorporated into the compositions.
- Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- the composition is especially adapted for administration into or around the eye.
- a composition can be adapted to be used as eye drops, or injected into the eye, e.g., using peribulbar or intravitreal injection.
- Such compositions should be sterile and substantially endotoxin-free, and within an acceptable range of pH. Certain preservatives are thought not to be good for the eye, so that in some embodiments a non-preserved formulation is used.
- Formulation of eye medications is known in the art, see, e.g., Ocular Therapeutics and Drug Delivery: A Multi - Disciplinary Approach , Reddy, Ed. (CRC Press 1995); Kaur and Kanwar, Drug Dev Ind Pharm.
- compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
- the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition.
- Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- Oral compositions generally include an inert diluent or an edible carrier.
- the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules, e.g., gelatin capsules.
- Oral compositions can also be prepared using a fluid carrier for use as a mouthwash.
- Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
- the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
- a lubricant such as magnesium stearate or Sterotes
- a glidant such as colloidal silicon dioxide
- the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
- a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
- Administration of a therapeutic composition described herein can also be by transmucosal or transdermal means.
- penetrants appropriate to the barrier to be permeated are used in the formulation.
- penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
- Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
- the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
- the compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
- suppositories e.g., with conventional suppository bases such as cocoa butter and other glycerides
- retention enemas for rectal delivery.
- compositions comprising nucleic acid compounds can also be administered by any method suitable for administration of nucleic acid agents.
- methods include gene guns, bio injectors, and skin patches as well as needle-free methods such as the micro-particle DNA vaccine technology disclosed in U.S. Pat. No. 6,194,389, and the mammalian transdermal needle-free vaccination with powder-form vaccine as disclosed in U.S. Pat. No. 6,168,587.
- needle-free methods such as the micro-particle DNA vaccine technology disclosed in U.S. Pat. No. 6,194,389, and the mammalian transdermal needle-free vaccination with powder-form vaccine as disclosed in U.S. Pat. No. 6,168,587.
- intranasal delivery is possible, as described in, inter alia, Hamajima et al., Clin. Immunol. Immunopathol., 88(2), 205-10 (1998).
- Liposomes e.g., as described in U.S. Pat. No.
- nucleic acid compounds comprise naked DNA, and are administered locally by injection, e.g., as described herein.
- the compositions are prepared with carriers that will protect the active ingredient against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
- a controlled release formulation including implants and microencapsulated delivery systems.
- Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.
- Such formulations can be prepared using standard techniques.
- the materials can also be obtained commercially, e.g., from Alza Corporation or Nova Pharmaceuticals, Inc.
- Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
- Dosage, toxicity and therapeutic efficacy of the compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.
- Compounds which exhibit high therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
- the data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans.
- the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- the therapeutically effective dose can be estimated initially from cell culture assays.
- a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture.
- IC50 i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms
- levels in plasma may be measured, for example, by high performance liquid chromatography.
- an “effective amount” is an amount sufficient to effect beneficial or desired results.
- a therapeutic amount is one that achieves a desired therapeutic effect. This amount can be the same or different from a prophylactically effective amount, which is an amount necessary to prevent onset of disease or disease symptoms.
- An effective amount can be administered in one or more administrations, applications or dosages.
- a therapeutically effective amount of a composition depends on the composition selected. The compositions can be administered one from one or more times per day to one or more times per week; including once every other day. The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present.
- treatment of a subject with a therapeutically effective amount of the compositions of the invention can include a single treatment or a series of treatments.
- compositions can be included in a container, pack, or dispenser together with instructions for administration.
- the therapeutic compositions described herein can include nucleic acid molecules encoding a selected protein, e.g., a protein listed in one of Tables 1-6, e.g., ALK1; these are useful, e.g., where an increase in the expression and/or activity of a selected protein is desirable.
- Nucleic acid molecules comprising expression constructs can be used, e.g., for in vivo or in vitro expression of a selected protein.
- expression can be restricted to a particular cell types so as to reconstitute the function of the selected protein in a cell, e.g., a cell in which that polypeptide is misexpressed, or in which expression of that polypeptide would produce a therapeutic benefit.
- a nucleic acid encoding the selected protein can be inserted in an expression vector, to make an expression construct.
- suitable vectors are known in the art, e.g., viral vectors including recombinant retroviruses, adenovirus, adeno-associated virus, and herpes simplex virus-1, adenovirus-derived vectors, or recombinant bacterial or eukaryotic plasmids.
- the expression construct can include: a coding region; a promoter sequence, e.g., a promoter sequence that restricts expression to a selected cell type, a conditional promoter, or a strong general promoter; an enhancer sequence; untranslated regulatory sequences, e.g., a 5′ untranslated region (UTR), a 3′UTR; a polyadenylation site; and/or an insulator sequence.
- a promoter sequence e.g., a promoter sequence that restricts expression to a selected cell type, a conditional promoter, or a strong general promoter
- an enhancer sequence e.g., untranslated regulatory sequences, e.g., a 5′ untranslated region (UTR), a 3′UTR; a polyadenylation site; and/or an insulator sequence.
- UTR 5′ untranslated region
- polyadenylation site e.g., adenylation site
- Expression constructs can be administered in any biologically effective carrier, e.g. any formulation or composition capable of effectively delivering the component gene to cells in vivo.
- Viral vectors transfect cells directly; plasmid DNA can be delivered with the help of, for example, cationic liposomes (e.g., Lipofectin) or derivatized (e.g. antibody conjugated), polylysine conjugates, gramicidin S, artificial viral envelopes or other such intracellular carriers, as well as direct injection of the gene construct or CaPO 4 precipitation.
- the nucleic acid is applied “naked” to a cell, i.e., is applied in a simple buffer without the use of any additional agents to enhance uptake. See, e.g., Current Protocols in Molecular Biology, Ausubel, F. M. et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard laboratory manuals.
- the nucleic acids can be introduced into a subject by any of a number of methods, each of which is familiar in the art.
- a pharmaceutical preparation of the gene delivery system can be introduced systemically, e.g. by intravenous injection, and specific transduction of the protein in the target cells occurs predominantly from specificity of transfection provided by a targeted gene delivery vehicle, cell-type or tissue-type expression due to the transcriptional regulatory sequences controlling expression of the receptor gene, or a combination thereof.
- initial delivery of the recombinant gene is more limited with introduction into the animal being quite localized.
- the gene delivery vehicle can be introduced by catheter (see U.S. Pat. No. 5,328,470) or by stereotactic injection (e.g. Chen et al. (1994) PNAS 91: 3054-3057).
- the therapeutic compositions described herein can include inhibitory nucleic acid molecules that are targeted to a selected target RNA encoding a protein listed in one of Tables 1-6, e.g., antisense, siRNA, ribozymes, and aptamers; these are useful, e.g., where a decrease in the expression and/or activity of a target protein is desirable.
- inhibitory nucleic acid molecules that are targeted to a selected target RNA encoding a protein listed in one of Tables 1-6, e.g., antisense, siRNA, ribozymes, and aptamers; these are useful, e.g., where a decrease in the expression and/or activity of a target protein is desirable.
- a decrease in the expression and/or activity of a target protein is desirable.
- a “gene walk” comprising a series of oligonucleotides of 15-30 nucleotides spanning the length of a target nucleic acid can be prepared, followed by testing for inhibition of target gene expression, to provide an antisense sequence.
- gaps of 5-10 nucleotides can be left between the oligonucleotides to reduce the number of oligonucleotides synthesized and tested.
- Similar methods can be used to generate siRNAs, aptamers, and ribozymes
- RNAi is a process whereby double-stranded RNA (dsRNA, also referred to herein as si RNAs or ds siRNAs, for double-stranded small interfering RNAs,) induces the sequence-specific degradation of homologous mRNA in animals and plant cells (Hutvagner and Zamore, Curr. Opin. Genet. Dev.:12, 225-232 (2002); Sharp, Genes Dev., 15:485-490 (2001)).
- RNAi can be triggered by 21-nucleotide (nt) duplexes of small interfering RNA (siRNA) (Chiu et al., Mol. Cell.
- RNA polymerase III promoters Zeng et al., Mol. Cell. 9:1327-1333 (2002); Paddison et al., Genes Dev. 16:948-958 (2002); Lee et al., Nature Biotechnol. 20:500-505 (2002); Paul et al., Nature Biotechnol. 20:505-508 (2002); Tuschl, T., Nature Biotechnol.
- the nucleic acid molecules or constructs can include dsRNA molecules comprising 16-30, e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in each strand, wherein one of the strands is substantially identical, e.g., at least 80% (or more, e.g., 85%, 90%, 95%, or 100%) identical, e.g., having 3, 2, 1, or 0 mismatched nucleotide(s), to a target region in the mRNA, and the other strand is complementary to the first strand.
- the dsRNA molecules can be chemically synthesized, or can transcribed be in vitro from a DNA template, or in vivo from, e.g., shRNA.
- the dsRNA molecules can be designed using any method known in the art; a number of algorithms are known, and are commercially available. Gene walk methods can be used to optimize the inhibitory activity of the siRNA.
- the inhibitory nucleic acid compositions can include both siRNA and modified siRNA derivatives, e.g., siRNAs modified to alter a property such as the pharmacokinetics of the composition, for example, to increase half-life in the body, as well as engineered RNAi precursors.
- siRNAs modified siRNA derivatives, e.g., siRNAs modified to alter a property such as the pharmacokinetics of the composition, for example, to increase half-life in the body, as well as engineered RNAi precursors.
- siRNAs can be delivered into cells by methods known in the art, e.g., cationic liposome transfection and electroporation.
- siRNA duplexes can be expressed within cells from engineered RNAi precursors, e.g., recombinant DNA constructs using mammalian Pol III promoter systems (e.g., H1 or U6/snRNA promoter systems (Tuschl (2002), supra) capable of expressing functional double-stranded siRNAs; (Bagella et al., J. Cell. Physiol. 177:206-213 (1998); Lee et al. (2002), supra; Miyagishi et al. (2002), supra; Paul et al. (2002), supra; Yu et al.
- mammalian Pol III promoter systems e.g., H1 or U6/snRNA promoter systems
- RNA Pol III Transcriptional termination by RNA Pol III occurs at runs of four consecutive T residues in the DNA template, providing a mechanism to end the siRNA transcript at a specific sequence.
- the siRNA is complementary to the sequence of the target gene in 5′-3′ and 3′-5′ orientations, and the two strands of the siRNA can be expressed in the same construct or in separate constructs.
- Hairpin siRNAs, driven by H1 or U6 snRNA promoter and expressed in cells, can inhibit target gene expression (Bagella et al. (1998), supra; Lee et al. (2002), supra; Miyagishi et al. (2002), supra; Paul et al. (2002), supra; Yu et al.
- Constructs containing siRNA sequence under the control of T7 promoter also make functional siRNAs when cotransfected into the cells with a vector expression T7 RNA polymerase (Jacque (2002), supra).
- an “antisense” nucleic acid can include a nucleotide sequence that is complementary to a “sense” nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to a TEF mRNA sequence.
- the antisense nucleic acid can be complementary to an entire coding strand of a target sequence, or to only a portion thereof.
- the antisense nucleic acid molecule is antisense to a “noncoding region” of the coding strand of a nucleotide sequence (e.g., the 5′ and 3′ untranslated regions).
- An antisense nucleic acid can be designed such that it is complementary to the entire coding region of a target mRNA, but can also be an oligonucleotide that is antisense to only a portion of the coding or noncoding region of the target mRNA.
- the antisense oligonucleotide can be complementary to the region surrounding the translation start site of the target mRNA, e.g., between the ⁇ 10 and +10 regions of the target gene nucleotide sequence of interest.
- An antisense oligonucleotide can be, for example, about 7, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, or more nucleotides in length.
- an antisense nucleic acid can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art.
- an antisense nucleic acid e.g., an antisense oligonucleotide
- an antisense nucleic acid can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used.
- the antisense nucleic acid also can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).
- the antisense nucleic acid molecule is an V-anomeric nucleic acid molecule.
- An V-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual (3-units, the strands run parallel to each other (Gaultier et al., Nucleic Acids. Res. 15:6625-6641 (1987)).
- the antisense nucleic acid molecule can also comprise a 2′-o-methylribonucleotide (Inoue et al. Nucleic Acids Res. 15:6131-6148 (1987)) or a chimeric RNA-DNA analogue (Inoue et al. FEBS Lett., 215:327-330 (1987)).
- the antisense nucleic acid is a morpholino oligonucleotide (see, e.g., Heasman, Dev. Biol. 243:209-14 (2002); Iversen, Curr. Opin. Mol. Ther. 3:235-8 (2001); Summerton, Biochim. Biophys. Acta. 1489:141-58 (1999).
- Target gene expression can be inhibited by targeting nucleotide sequences complementary to a regulatory region (e.g., promoters and/or enhancers) to form triple helical structures that prevent transcription of the SptS gene in target cells.
- a regulatory region e.g., promoters and/or enhancers
- the potential sequences that can be targeted for triple helix formation can be increased by creating a so called “switchback” nucleic acid molecule.
- Switchback molecules are synthesized in an alternating 5′-3′,3′-5′ manner, such that they base pair with first one strand of a duplex and then the other, eliminating the necessity for a sizeable stretch of either purines or pyrimidines to be present on one strand of a duplex.
- Ribozymes are a type of RNA that can be engineered to enzymatically cleave and inactivate other RNA targets in a specific, sequence-dependent fashion. By cleaving the target RNA, ribozymes inhibit translation, thus preventing the expression of the target gene. Ribozymes can be chemically synthesized in the laboratory and structurally modified to increase their stability and catalytic activity using methods known in the art. Alternatively, ribozyme genes can be introduced into cells through gene-delivery mechanisms known in the art.
- a ribozyme having specificity for a target nucleic acid can include one or more sequences complementary to the nucleotide sequence of a cDNA encoding a protein described herein, and a sequence having known catalytic sequence responsible for mRNA cleavage (see U.S. Pat. No. 5,093,246 or Haselhoff and Gerlach Nature 334:585-591 (1988)).
- a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a target mRNA. See, e.g., Cech et al. U.S. Pat. No.
- a target mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel and Szostak, Science 261:1411-1418 (1993).
- nucleic acid molecules described herein can be administered to a subject (e.g., by direct injection at a tissue site), or generated in situ.
- inhibitory nucleic acid molecules can be administered such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a target protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation.
- Nucleic acid molecules that encode an active agent are generally administered such that they enter a cell and are expressed therein.
- the nucleic acid molecules can be administered selectively, e.g., by local injection, or modified to target selected cells (e.g., by the use of a tissue-specific promoter) and then administered systemically.
- nucleic acid molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the nucleic acid nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens.
- the nucleic acid nucleic acid molecules can also be delivered to cells using vectors known in the art, e.g., as described herein.
- vector constructs in which the inhibitory nucleic acid nucleic acid molecule is placed under the control of a promoter e.g., a strong promoter can be used.
- a promoter e.g., a strong promoter
- polypeptides and nucleic acids described herein are useful in the treatment of disorders associated with neovascularization, i.e., abnormal angiogenic processes, e.g., disorders in the formation of blood vessels.
- disorders associated with neovascularization i.e., abnormal angiogenic processes, e.g., disorders in the formation of blood vessels.
- the disorder will stem from overformation of blood vessels, or formation of blood vessels in an unwanted area, e.g., in the avascular regions of the eye, e.g., retinopathies, or in a tumor, e.g., a cancerous or benign tumor.
- the ophthalmological disorder can be age-related macular degeneration, where new blood vessels grow under the retina, or diabetic retinopathy, where abnormal vessels grow on top of the retina.
- Other ophthalmological disorders include retinopathy of prematurity, corneal graft rejection, glaucoma, herpetic and infectious keratitis, ocular ischemia, neovascular glaucoma, corneal, uveal and iris neovascularization, orbital and eyelid tumors, Stevens Johnson Syndrome, ocular cicatricial pemphigoid, wounds, and ocular surface diseases.
- the disorder can be characterized by, for example, corneal, retinal, choroidal, uveal, or iris neovascularization
- the disorder may stem from the formation of blood vessels that deliver blood to a tissue, e.g., a primary or metastatic cancerous or benign tumors, e.g., cancer.
- a metastatic tumor can arise from a multitude of primary tumor types, including but not limited to those of prostate, colon, lung, breast and liver origin.
- cancer refers to cells having the capacity for autonomous growth, i.e., an abnormal state or condition characterized by rapidly proliferating cell growth.
- hyperproliferative and neoplastic disease states may be categorized as pathologic, i.e., characterizing or constituting a disease state, or may be categorized as non-pathologic, i.e., a deviation from normal but not associated with a disease state.
- pathologic i.e., characterizing or constituting a disease state
- non-pathologic i.e., a deviation from normal but not associated with a disease state.
- the term is meant to include all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness.
- “Pathologic hyperproliferative” cells occur in disease states characterized by malignant tumor growth.
- Examples of non-pathologic hyperproliferative cells include proliferation of cells associated with wound repair; thus, the methods include administration of a compound identified by a method described herein to maintain avascularity during wound healing.
- the ophthalmological disorder is a wound, including both accidental as well as intentional wounds (e.g., surgical wounds).
- the ophthalmological disorder is a cancer of the eye, e.g., eyelid tumors, e.g., malignant eye lid tumors, benign eye lid tumors, basal cell carcinoma, squamous cell carcinoma, sebaceous cell carcinoma, and malignant melanoma; conjunctival tumors, e.g., pigmented conjunctival tumors, melanoma and primary acquired melanosis with atypia, squamous conjunctival neoplasia, conjunctival lymphoma, and Kaposi's Sarcoma; iris tumors, e.g., iris melanoma, iris pigment epithelial cyst, anterior uveal metastasis, and pearl cyst of the iris; infiltrative intraocular tumors, e.g., multiple myeloma, lymphoma, and leukemia; choroidal tumors, e.g., choroidal tumors,
- to “treat” means to ameliorate at least one symptom associated with abnormal angiogenesis as well as reduce neovascularization.
- to “treat” includes inhibition of the growth of blood vessels resulting in a lack of nutrients for the tumors and/or cancer cells needed by the tumor for its growth. Tumors and growths will decrease in size and possibly disappear.
- Administration of a therapeutically effective amount of a composition for the treatment of arthritic conditions will result in decreased blood vessel formation in cartilage, specifically joints, resulting in increased mobility and flexibility in these regions.
- administration of a therapeutically effective amount of a composition described herein will reduce the formation of extraneous blood vessels in the retina, resulting in unobstructed or less obstructed vision.
- administration of a therapeutically effective amount of a composition described herein will inhibit the growth and/or further formation of blood vessels, thereby inhibiting the formation of any lesions and/or tumors that arise.
- the invention includes methods for screening test compounds, e.g., polypeptides, polynucleotides, inorganic or organic large or small molecule test compounds, to identify agents useful in the treatment of disorders associated with neovascularization, e.g., as described herein.
- test compounds e.g., polypeptides, polynucleotides, inorganic or organic large or small molecule test compounds
- small molecules refers to small organic or inorganic molecules of molecular weight below about 3,000 Daltons.
- small molecules useful for the invention have a molecular weight of less than 3,000 Daltons (Da).
- the small molecules can be, e.g., from at least about 100 Da to about 3,000 Da (e.g., between about 100 to about 3,000 Da, about 100 to about 2500 Da, about 100 to about 2,000 Da, about 100 to about 1,750 Da, about 100 to about 1,500 Da, about 100 to about 1,250 Da, about 100 to about 1,000 Da, about 100 to about 750 Da, about 100 to about 500 Da, about 200 to about 1500, about 500 to about 1000, about 300 to about 1000 Da, or about 100 to about 250 Da).
- test compounds can be natural products or members of a combinatorial chemistry library.
- a set of diverse molecules can be used to cover a variety of functions such as charge, aromaticity, hydrogen bonding, flexibility, size, length of side chain, hydrophobicity, and rigidity.
- Combinatorial techniques suitable for synthesizing small molecules are known in the art, e.g., as exemplified by Obrecht and Villalgordo, Solid - Supported Combinatorial and Parallel Synthesis of Small-Molecular-Weight Compound Libraries , Pergamon-Elsevier Science Limited (1998), and include those such as the “split and pool” or “parallel” synthesis techniques, solid-phase and solution-phase techniques, and encoding techniques (see, for example, Czarnik, Curr.
- Libraries screened using the methods of the present invention can comprise a variety of types of test compounds.
- a given library can comprise a set of structurally related or unrelated test compounds.
- the test compounds are peptides or peptidomimetic molecules.
- the test compounds are nucleic acids, e.g., antisense, RNAi, or aptamers.
- test compounds and libraries thereof can be obtained by systematically altering the structure of a first test compound, e.g., a first test compound that is structurally similar to a known natural binding partner of the target polypeptide, or a first small molecule identified as capable of binding the target polypeptide, e.g., using methods known in the art or the methods described herein, and correlating that structure to a resulting biological activity, e.g., a structure-activity relationship study. As one of skill in the art will appreciate, there are a variety of standard methods for creating such a structure-activity relationship.
- the work may be largely empirical, and in others, the three-dimensional structure of an endogenous polypeptide or portion thereof can be used as a starting point for the rational design of a small molecule compound or compounds.
- a general library of small molecules is screened, e.g., using the methods described herein.
- a test compound is applied to a test sample, e.g., a cell or living tissue or organ, e.g., an eye, and one or more effects of the test compound is evaluated.
- a test sample e.g., a cell or living tissue or organ, e.g., an eye
- one or more effects of the test compound is evaluated.
- the ability of the test compound to modulate expression of one or more of the proteins listed in Tables 1-6 can be evaluated.
- the ability of the test compounds to modulate expression of one or more of the proteins listed in Tables 1-6 can be evaluated. Methods for evaluating each of these effects are known in the art. For example, ability to modulate expression of a protein can be evaluated at the gene or protein level, e.g., using quantitative PCR or immunoassay methods.
- high throughput methods e.g., protein or gene chips as are known in the art (see, e.g., Ch. 12, Genomics, in Griffiths et al., Eds., Modern Genetic Analysis, 1999, W. H. Freeman and Company; Ekins and Chu, Trends in Biotechnology, 1999, 17:217-218; MacBeath and Schreiber, Science 2000, 289(5485):1760-1763; Simpson, Proteins and Proteomics: A Laboratory Manual , Cold Spring Harbor Laboratory Press; 2002; Hardiman, Microarrays Methods and Applications: Nuts & Bolts , DNA Press, 2003), can be used to detect an effect on two, three, four, five or more of the proteins listed in Tables 1-6.
- hits e.g., test compounds that demonstrate an ability to modulate, i.e., cause an increase or decrease in levels, expression, or activity, of one or more of the proteins listed in Tables 1-6
- the invention includes screening a first library of small molecules using a method known in the art and/or described herein, identifying one or more hits in that library, subjecting those hits to systematic structural alteration to create a second libraries of compounds structurally related to the hit, and screening the second library using the methods described herein.
- hits can be considered candidate therapeutic compounds, useful in treating disorders associated with neovascularization, as described herein.
- a variety of techniques useful for determining the structures of “hits” can be used in the methods described herein, e.g., NMR, mass spectrometry, gas chromatography equipped with electron capture detectors, fluorescence and absorption spectroscopy.
- the invention also includes compounds identified as “hits” by the methods described herein, and methods for their administration and use in the treatment, prevention, or delay of development or progression of a disorder described herein.
- Test compounds identified as candidate therapeutic compounds can be further screened by administration to an animal model of a disorders associated with neovascularization, as described herein.
- the animal can be monitored for a change in the disorder, e.g., for an improvement in a parameter of the disorder, e.g., a parameter related to clinical outcome.
- the parameter is unwanted vascularisation, and an improvement would be a decrease in the levels of vascularisation.
- non-rodent e.g., human samples, e.g., samples obtained from human fetuses at different stages of development, as well as samples at substantially the same stage of development, but in pathological and non-pathological stages.
- a surgical specimen from a subject with a disorder e.g., retinopathy of prematurity or retrolental fibroplasias
- a normal, unaffected control e.g., an age-matched control.
- a total of 44 C57BL/6 newborn male and female litters were obtained from Jackson Laboratories (Bar Harbor, Me.) were used for the experiments described herein.
- the age of the newborn mice was expressed in terms of post-gestational days.
- the newborn mice were sacrificed on post-gestational days 1, 4, 8, 16, 24, and 30 (i.e., P1, p4, p16, p24, and P30).
- Four eyes per each post-gestational day were used for the histological study.
- For the lens and vitreous protein extraction were used 20 eyes of P 1 mice, 20 eyes of P 4 mice, 12 eyes of P 8 mice and 12 eyes of P 16 mice.
- mice used for the histological study were perfused with 4% paraformaldehyde in PBS under general anesthesia administered by intramuscular injection of a mixture of ketamine (200 mg/kg) and xylazine (10 mg/kg).
- the eyes were removed and immerse in buffered neutral formalin solution (100 ml 40% formalin, 900 ml distilled water, 4.0 gm monobasic sodium phosphate, 6.5 gm dibasic sodium phosphate), then they were embedded into paraffin and were cut in tissue slices of 5 micron each with a microkeratome. Each sample was stained with Hematoxylin-Eosin (H-E) staining
- the PM of the newborn mice showed as a dense plexus of capillaries that began to regress on post-gestation day 4 and become vestigial on day 8. The PM disappeared completely in all eyes on day 16.
- the radial branches of the TVL that lie on the lens surface are prominent until P4, particularly posterior to the lens equator. Later there is a gradual disappearance of the TVL and it is completely disappeared in about one third of eyes examined on day P24 and in all eyes on day P30.
- the HA arose from the optic disc as a single thick proximal trunk and entered the vitreous branching in several vessels of the VHP and running anteriorly to the posterior pole of the lens. As the whole eye developed in size and the volume of the vitreous increased, the VHP run toward the lens joining the TVL and became less prominent. Involution of HA and VHP has begun by day 1 and from day 12 to day 30 there is a gradual disappearance of those vessels.
- This example describes the use of a proteomic approach to try to decipher the biochemical events coexisting with the progressive regression of the HVS.
- the proteomic analysis provided an opportunity to compare different stages of the mouse eye development, to identify specific qualitative and quantitative protein changes, associated with the early maintenance and later regression of the HVS.
- mice To prepare mouse lens and vitreous for 2-D electrophoresis, 32 newborn mice were decapitated. The eyes were enucleated and then frozen at ⁇ 80 degrees Celsius. The frozen eyes were scraped with a blade to remove cornea, aqueous humor, conjunctiva, sclera, iris, ciliary body, uvea and retina and to obtain the lens surrounded by PM and TVL and the primary vitreous containing VHP.
- the scraping was done on a dry-ice bed to prevent the specimen from warming up and the consequent protein denaturation, melting of the tissue and contamination of the specimen by eye components different from lens and primary vitreous.
- the homogenate was transferred into 1.5 ml micro centrifuge tubes and the protein extracts were cleared by centrifugation at 14,000 rpm for 20 minutes at 4° Celsius to remove particulates.
- the protein concentration of the cleared supernatants was determined by using a compatible protein assay (Biorad Laboratories, Hercules, Calif.), and samples were stored at ⁇ 80° Celsius until use.
- a time course experiment was designed to examine the changes in protein expression at the critical time points throughout the HVS regression process.
- Protein spots that were reproducibly differentially expressed in P1 and P 16 were considered for protein identification. The statistical significance of changes was evaluated using the Phoretix 2D software.
- Gel bands were excised and minced into approximate 1 mm 3 pieces with a sterile razor blade of the Xcise technology platform from Proteome system and placed into a sterile microcentrifuge. Gel pieces were destained 3 times by adding 200 uL of 25 mM NH 4 HCO 3 in 50% acetonitrile, dried using a SpeedVac® concentrator, alkylated and digested with trypsin (Promega, Madison, Wis., USA) in 50 mM of ammonium bicarbonate overnight to release tryptic peptides. Samples were dried in a SpeedVac® to remove residual ammonium bicarbonate. Peptides were resuspended in 50% acetonitrile with 1% formic acid solution. About 30% of the digest was subjected to nano-LC ESI IT MS/MS analysis.
- a Surveyor LC pump (ThermoElectron, CA) with a C18 trapping column (300 um i.d. ⁇ 1 mm, Dionex, CA) and a self-packed reversed-phase column 75 mm i.d. ⁇ 15 cm (Magic C18AQ, 3 um) was used for nano-LC experiments.
- An LCQ Deca XP Plus ESI mass spectrometer (Thermo Electron, CA) was used for all the experiments.
- MS/MS data-dependent acquisition a full MS scan between 400 and 2000 m/z was followed by five full MS/MS scans for the five most intense ions from the MS scan in all ESI.
- MS/MS data-dependent acquisition followed by database searching with SEQUEST (BioWorks 3.1, ThermoElectron) allowed protein identification.
- Fully tryptic peptides were matched with SEQUEST at a delta correlation ( )Cn) of greater than 0.08 and correlation (Xcorr) greater than 1.9, 2.2 and 3.5 for charged states of +1, +2 and +3, respectively.
- the search was performed against the whole NCBInr mouse protein sequence database, and human homologs (e.g., proteins with at least 75% identity to the mouse sequence) were identified (www.ncbi.nml.nih.gov).
- Protein expression maps were generated in triplicate per each time point obtaining a reproducible separation of the protein spots on the 2-DE gels. On average, up to 1300 proteins spots could be detected in each gel with the Phoretix 2D imaging analysis software. This software provides the ability to “warp” different gel images using mathematical algorithms, improving the quality of the protein spot matching between the gels and allowing easy detection of the differences among the gels.
- the 2-DE gels demonstrated a progressive lessening in the number and in the intensity of the protein spots from P1 to P16, particularly of the proteins that migrated in the area corresponding to pI 4 to pI 7 and M r 30 kDa to 90 kDa.
- the warping of P1, P4 and P8 with P16 revealed the presence of 20 protein spots in P16 that are not present in the other gels.
- protein product mKIAA0585 protein 28972291 (—) 32.
- protein product mKIAA0650 protein 37360026 (—) 33.
- protein product 1333921 1333921 (—) 35.
- protein product 26335149 26335149 (—) 36.
- RAD50 homolog 6679609 19924130 37. Solute carrier family 20 28204938 58761541 38.
- IPG nonlinear immobilized pH gradient
- IPG strips were prepared for the second dimension by two sequential 10 minute incubations in 6 M urea, 50 mM Tris (pH 8.8), 30% glycerol, 2% SDS, and 0.001% bromophenol blue, containing, alternately, 2% DTT or 2.5% iodoacetamide.
- Second-dimension separation was then performed on 4-20% SDS-PAGE gels (Biorad Laboratories, Hercules Calif.) with the first-dimension IPG strip embedded in 0.5% agarose at the top. Proteins on gel were fixed in 10% acetic acid and 20% methanol for 1 hour and were then stained using SYPRO Rubin Protein Gel stain (Biorad Laboratories, Hercules Calif.). In total, 12 gels with samples were prepared and subjected to analysis for the first experiment and 6 for the second experiment.
- the gels were warped the P4 map was matched with the P16 map to compare and identify proteins that were differentially expression in these gels. Of the proteins with differential expression, a number of spots were selected.
- Tables 3-4 Table 3 lists proteins that were identified as particularly interesting targets, due to their known function.
- Ca ⁇ 2+>dependent activator 6753238 34452715 protein for secretion 10.
- calcium binding protein 2639022 7656952 11.
- Calnexin 56206506 10716563 12.
- cathepsin 3 precursor 19424144 (—) 13.
- Cathepsin D 26101892 4503143 14.
- Cofilin 1 37194891 5031635 16.
- Creatine kinase brain 10946574 (—) 17.
- Cttn protein 15030315 21707902 18.
- development- and differentiation- 51827426 (—) enhancing factor 2; PYK2 C homolog 19.
- GRP1 general receptor for 26094386 32171221 phosphoinositides 1-associated scaffold protein 27.
- NRCA_MOUSE Neuronal cell 26333200 (—) adhesion molecule precursor (Nr- CAM) (NgCAM-related 35. PDZ domain containing homolog 26325701 58533161 36.
- Table 4 is a list of those proteins with unknown function that are differentially expressed during development of the HVS.
- protein product 26338367 unknown 26338367 15. protein product 26329025 unknown 26329025 16.
- cDNA 4930513F16 29789229 IQ calmodulin-binding motif containing protein 34.
- cDNA 4930578C19 30424860 nucleotide apoptosis triphosphate hydrolases 36.
- each gel was incubated in the dark in 50 mL of Pro-Q® Diamond phosphoprotein gel stain with gentle agitation for 75-120 minutes (Molecular Probes Laboratories); each gel was destained for two times in 80-100 mL of Destain Solution (Molecular Probes Laboratories) at room temperature, protected from light. Images of each gel were taken with the Image acquisition system Molecular Imager FX Pro Plus. Every gel was then stained for three hours with SYPRO Rubin Protein gel Stain (Biorad Laboratories, Hercules Calif.), and proteins on the gel were fixed twice in 10% acetic acid and 20% methanol for 1 hour. Images of each gel were taken with the Image acquisition system Molecular Imager FX Pro Plus.
- the proprietary fluorescent stain of Pro-Q® Diamond phosphoprotein gel staining allows direct in-gel detection of phosphate groups attached to tyrosine, serine or threonine residues.
- the comparison between the images obtained from P1 and P16 gels stained with the phosphostain showed a different pattern of protein activation. Thirteen protein spot were identified with mass spectroscopy that were present in P1 but not in P16, and nine protein spots present in P16 but not in P1. Proteins identified by this method are listed in Table 5.
- ALK1 Activin Receptor-Like Kinase 1
- the activin receptor-like kinase 1 (ALK1), a TGF-beta1 type I receptor, plays an inhibitory role in angiogenesis and vascular development. Mutations of ALK1 gene are linked to human type II hereditary hemorrhagic telangiectasia. Our purpose was to develop a mouse model to study the differential expression of proteins during the phase of Hyaloid Vascular System (HVS) regression and determine the role of ALK1 in this model.
- HVS Hyaloid Vascular System
- the generated protein expression maps showed reproducible separation of the protein spots on the 2 Dimension Electrophoresis gels. Up to 1400 proteins spots were detected per gel. Progressive decrease in the number and intensity of the protein spots occurred from P1 to P16, particularly in the area corresponding to pI 4-7 and M r 30-90 kDa. Twenty protein spots in the P16 gels were not present in the P1 gels.
- mice were sacrificed on post-natal days 1, 4 and 16.
- a dry ice bed frozen mouse eyes were scraped with a blade (Beaver #15) to remove the cornea, conjunctiva, sclera, ciliary body, uvea, and retina, leaving the lens surrounded by the PM, TVL, and primary vitreous (containing VHP).
- the dry ice bed was used to prevent warming of the specimen, tissue melting, and subsequent protein denaturation.
- Samples of P1, P4 and P16 were pooled and independently solubilized in 250 ⁇ l of total protein extraction buffer 7 M urea, 2 M thiourea, 1% (w/v) ASB-14 detergent, 40 mM Tris base, 0.001% bromophenol blue, 20% carrier ampholyte (Biorad Laboratories, Hercules, Calif.) and 2 ⁇ l of 200 mM tributylphosphine by mechanically homogenizing them with an electrical tissue homogenizer for 5 min on ice. The homogenates of the protein extracts were cleared by centrifugation for 20 min at 14,000 rpm and 4° C. to remove particulates. Protein concentration of the supernatants was determined by protein assay (Biorad Laboratories).
- IPG immobilized pH gradient
- Gel bands (differentially expressed proteins) from 2-DE gels were excised, minced into approximate 1 mm 3 pieces with a sterile razor blade of the Xcise technology platform from Proteome system, alkylated, and digested with trypsin (Promega, Madison, Wis.). Peptides were resuspended in 50% acetonitrile with 1% formic acid solution and subjected to nano-LC ESI IT MS/MS analysis.
- a Surveyor LC pump (Thermo Electron, San Jose, Calif.) with a C18 trapping column (300 ⁇ m i.d. ⁇ 1 mm, Dionex, Sunnyvale, Calif.) and a reversed-phase column 75 ⁇ m i.d. ⁇ 15 cm (Magic C18AQ, 3 ⁇ m) was used for nano-LC experiments.
- An LCQ Deca XP plus ESI mass spectrometer was used for all the experiments.
- MS/MS data-dependent acquisition followed by database searching with SEQUEST (BioWorks 3.1, Thermo Electron, San Jose, Calif.) allowed protein identification.
- Fully tryptic peptides were matched with SEQUEST at a delta correlation (ACn) of greater than 0.08 and correlation (Xcorr) greater than 1.9, 2.2, and 3.5 for charged states of +1, +2, and +3, respectively.
- Peptide mass fingerprints (PMFs) were searched for matches with the virtually generated tryptic protein masses of the NCBInr mouse protein sequence database (available at ncbi.nml.nih.gov). All databases were provided in the public domain by the host institutions. Proteins were noted as differentially expressed if they could not be located at the corresponding position on the 2-DE gel of the other time point.
- Protein expression maps were generated in triplicate for each time point, obtaining a reproducible separation of the protein spots on the 2-DE gels. Up to 1400 protein spots could be detected in each gel with the Phoretix 2D image analysis software ( FIG. 1A ). This software allows the possibility to warp different gel images to improve the quality of the protein spot matching between the gels and allow an easy detection of the differences among the gels.
- the 2-DE gels were analyzed, and a progressive decrease in the number and intensity of the protein spots from P1 to P16 was observed, particularly of the migrated proteins in the area corresponding to pI 4-7 and M w 30-90 kDa ( FIG. 1B-C ).
- OCT optimal cutting temperature
- BSA bovine serum albumin
- rabbit anti-ALK1 polyclonal antibody courtesy of Dr. D. A. Marchuck, University of North Carolina
- a secondary antibody used was fluorescein-conjugated, affinity-purified anti-rabbit IgG antibody (Jackson ImmunoResearch Laboratories, West Grove, Pa.) at a concentration of 1:400.
- Negative controls were prepared in the same manner, with 1% BSA without primary antibody. Immunostained sections were viewed with a Leica TCS SP2 CLSM confocal laser scanning microscope (Leica, Heidelberg, Germany).
- the confocal immunohistochemical staining demonstrated that ALK1 is localized in the endothelial cells of the TVL at P1, P4 and P16.
- mice corneas were injected with naked DNAs of pEF (vector) and pEF-ALK1.
- Plasmid construction and corneal naked DNA injection pYX-Asc-ALK1 cDNA was purchased from ATCC (Manassas, Va.). Plasmids were purified using a Qiagen kit (Valencia, Calif.) according to the manufacturer's instructions.
- the mouse ALK1 DNA was sequenced and subcloned into pEF expression vector.
- An Elongation Factor 1 alpha promoter (pEF; Kim et al., Gene. 1990 Jul. 16; 91(2):217-23) was used to drive the expression of the ALK1 gene.
- Mouse corneas received a DNA injection of 5 ⁇ A of pEF-ALK1 (400 ng/ ⁇ l) or an injection of 5 ⁇ A of vector (400 ng/ ⁇ l). An antibiotic ophthalmic ointment was used after surgery.
- Pellets were made of the slow-release polymer Hydron (polyhydroxyethyl-methacrylate), which contained a combination of 45 ng/pellet of sucralfate (Sigma) and 120 ng/pellet of bFGF (R&D Systems, Minneapolis, Minn.), as previously described by Kenyon et al., Invest Ophthalmol V is Sci 37, 1625-1632 (1996).
- a suspension of sterile saline containing the appropriate amount of recombinant bFGF and sucralfate was made and concentrated using a speed-vacuum for 8 minutes.
- 10 ⁇ l of 12% Hydron in ethanol was added to this suspension.
- the suspension was then deposited onto a sterilized nylon mesh (LAB Pak, Sefar America, Depew, N.Y.) and embedded between the fibers.
- the resulting grid of 10 mm ⁇ 10 mm squares was allowed to dry on a sterile Petri dish for 60 min.
- the fibers of the mesh were pulled apart under a microscope and, among the approximately 100 pellets produced, 30 to 40 uniformly-sized pellets of 0.4 ⁇ 0.4 ⁇ 0.2 mm were selected for implantation. All procedures were performed under sterile conditions.
- corneal micropockets were created with a modified von Graefe knife in C57BL/6 mice. Hydron pellets containing 120 ng of human basic FGF were implanted into the corneal pockets.
- the corneas were routinely examined and photographed in five positions: en face, superior, inferior, nasal, and temporal with a slit lamp biomicroscope (Nikon FS-2, Tokyo, Japan) on days 1, 4, 7, and 14 post-pellet implantation.
- the photographs were digitized and the images were resolved at 300 pixels/inch and analyzed with the NIH ImageJ image program (NIH, Bethesda, Md.).
- NIH ImageJ program was used to calculate the area of corneal neovascularization areas. Statistical analysis was performed with the student T-test.
- the ALK1 plus pellet group ( FIG. 2M-P ) showed no evidence of corneal NV at any time point after pellet implantation.
- the group receiving vector control plus pellets ( FIG. 2I-L ) began to develop corneal NV at day 4, and the new vessels continued to grow toward the pellet area at days 7 and 14.
- the no-pellet control groups [ALK1 naked DNA ( FIG. 2E-H ) and vector naked DNA ( FIG. 2A-D )] did not induce corneal NV.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates, at least in part, to methods and compositions for treating and diagnosing disorders associated with neovascularization, and methods for identifying targets and compositions used in treating and diagnosing such disorders.
Description
- This application is a continuation of U.S. application Ser. No. 13/007,202, which was filed on Jan. 14, 2011, which is a continuation of U.S. application Ser. No. 11/363,402, which was filed on Feb. 24, 2006, which claims the benefit under 35 USC §119(e) of U.S. Provisional Patent Application Ser. Nos. 60/656,168, filed on Feb. 24, 2005, and 60/719,998, filed on Sep. 23, 2005. The entire contents of each of these applications is hereby incorporated by reference.
- This invention relates to methods and compounds for promoting vessel regression, e.g., to treat disorders associated with neovascularization.
- The hyaloid vascular system (HVS) is a transiently existing network of capillaries that function to nourish the immature lens and primary vitreous of the developing eye. The hyaloid artery (HA) runs from the back of the eye to the embryonic lens giving rise to a capillary plexus that surrounds the lens, consisting of the vasa hyaloidea propria (VHP), the tunica vasculosa lentis (TVL) and the pupillary membrane (PM). The HVS provides a useful system to investigate physiologically relevant angiogenesis and vascular remodeling processes.
- The first elements of the human hyaloid vasculature to undergo regression are the VHP, followed by the TVL, PM and lastly the main hyaloid trunk, commencing at 12 weeks of gestation (WG) and culminating in the involution of the entire hyaloid by 35-36 WG (Mann I. The Development of the Human Eye. Pp 201-32. Grune & Stratton Inc: New York, 1964). In humans, failure of the hyaloid vascular system to regress can lead to a condition known as persistent hyperplastic primary vitreous (PHPV), which can result in permanent blindness if left untreated.
- Mitchell and coworkers showed that in mice the hyaloid vascular system is first recognized at embryonic day 10.5 (E10.5), is complete by E13.5 and regresses postnatally prior to eyelid opening (Mitchell C A, et al., Dev. Dyn. 213(3):322-33 (1998)). During mouse development, the longer branches of the TVL and the longer hyaloid vessels are removed by post-gestational day 16 (P16) (Mitchell C A, et al., Dev. Dyn. 213(3):322-33 (1998)). Ito et al. presented partially similar results, showing that the PM had completely disappeared by P16, and the VHP had disappeared between P12 and P16, but the TVL and the hyaloid artery remained even at P16 (Ito and Yoshioka, Anat. Embryol. (Berl). 200(4):403-11 (1999)). Smith showed a gradual disappearance of the TVL and hyaloid artery from P14 to P30 (Smith, Systematic evaluation of the Mouse Eye: Anatomy, Pathology, and Biomethods. Pp 45-63. Sunders, 2002).
- Previous hypotheses of the mechanism of regression of the hyaloid vascular system included the following:
- A. The reduction or the cessation of the blood flow into the HVS was thought to be one of the major triggering factors of the regression in these vessels. A change in the blood flow distribution (Bischoff et al., Graefes Arch. Clin. Exp. Ophthalmol. 220 (6):257-63 (1983)) and competition between the blood vessels in the retina and the lens for the blood flow can lead to the degeneration of the HVS when the retinal blood vessels become larger and require more nutrients.
- B. Vascular obstruction, physical vascular stretching, localized circulatory stasis, and arterial vasoconstriction were regarded as triggering factors of the regression of the HVS (Jack, Am. J. Ophthalmol. 74 (2):261-72 (1972); Latker and Kuwabara, Invest. Ophthalmol. Vis. Sci. 21 (5):689-99 (1981)). The regression occurs first in those vessels that were hemodynamically disadvantaged and consequently had less blood flow.
- C. Meeson et al. have shown that the occurrence of apoptosis in the PM strictly correlated to the flow status; as the flow decreased the appearance of apoptosis in capillaries increased (Meeson et al., Development. 122(12):3929-38 (1996)). The same correlation may exist in the hyaloid vascular system. As the main role of the HVS is supposed to be to nourish the retina before the maturation of retinal vessels, the HVS may regress after the completion of these vessels.
- D. Macrophages may also be required in the programmed regression of the PM and the HVS (Lang and Bishop, Cell. 13; 74 (3):453-62 (1993); Lang et al., Development. 120 (12):3395-403 (1994); Diez-Roux and Lang, Development. 124 (18):3633-8 (1997)).
- E. The anti-angiogenic ability of the vitreous humor and vitreous extracts may also be important in the regression of the TVL (Preis et al., Am. J. Ophthalmol. 84 (3):323-8 (1977); Felton et al., Arch. Ophthalmol. 97 (9):1710-3 (1979); Lutty et al., Invest. Ophthalmol. Vis. Sci. 24 (1):52-6 (1983); Taylor and Weiss, Biochem Biophys Res Commun. 133 (3):911-6 (1985); Zhu et al., Aust. N. Z. J. Ophthalmol. 25 Suppl 1:S57-60 (1997); Ramesh et al., Br. J. Ophthalmol. 88 (5):697-702 (2004)). Hyalocytes play also a role in the regression of the TVL (McMenamin et al., Invest. Ophthalmol. V is Sci. 43 (7):2076-82 (2002)). Lutty et al. have demonstrated that the hyalocytes produce and process transforming growth factor-β (TGF-β) which may inhibit is the proliferation of the vascular endothelial cells in this system (Lutty et al., Invest. Ophthalmol. Vis. Sci. 34 (3):477-87 (1993)).
- F. Several survival factors may protect cells from apoptosis, including fibroblast growth factor (FGF), platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF). A reduction in levels of these growth factors below a critical threshold may lead to the induction of an apoptotic program.
- The role of VEGF in the maintenance of the VHP is not clear. Feenay et al. demonstrated that the TVL degeneration was unexpectedly uninfluenced by treatment with a VEGF A antibody, suggesting that programmed regression is independent of VEGF A, or that the development and maturation of the lens had gone beyond the point of the plasticity and susceptibility to certain growth factors (Feeney et al., Invest. Ophthalmol. Vis. Sci. 44 (2):839-47 (2003)).
- The present invention is based, at least in part, on the results of proteomic analysis of the mouse lens and vitreous during postnatal development, which identified novel proteins that contribute to regression of the hyaloid system. Among other proteins, two-dimensional electrophoresis and mass spectrometry of the developing mouse lens and vitreous identified activin receptor-like kinase-1 (ALK1) as a differentially expressed protein during HVS regression; immunohistochemical staining demonstrated the localization of ALK1 in the TVL; and overexpression of ALK1 in the cornea resulted in inhibition of bFGF-induced corneal neovascularization in vivo. Activin receptor-like kinase-1 (ALK1) activates Smads1, 5 and 8 which down-regulate VEGF production. In contrast, ALK5 activates Smads2 and 3 which up-regulate VEGF production (Goumans et al., EMBO. J. 21, 1743-1753 (2002)). Expression of ALK1 in blood vessels and mutations of the ALK1 gene in patients with human type II hereditary hemorrhagic telangiectasia, a multi-systemic vascular dysplasia, suggests that ALK1 may play an important role during normal vascular development (Oh et al., Proc Natl Acad Sci USA 97, 2626-2631 (2000)).
- Thus, ALK1 polypeptides and nucleic acids are useful compositions and targets for treating disorders associated with neovascularization (NV), and in cancer therapy.
- In one aspect, the invention provides methods for treating patients who have a disorder associated with neovascularization, e.g., an ophthalmological disorder associated with neovascularization. The methods include administering to the patient a therapeutically effective amount of an ALK1 polypeptide or nucleic acid composition, e.g., as described herein. The invention further includes therapeutic compositions including the ALK1 polypeptides or nucleic acids described herein, as well as inhibitors and/or agonists thereof, and methods for identifying such compounds.
- Ophthalmological disorders associated with neovascularization include eye cancer, age-related macular degeneration, retinopathy of prematurity, corneal graft rejection, glaucoma, diabetic retinopathy, wounds, age-related macular degeneration, herpetic and infectious keratitis, ocular ischemia, neovascular glaucoma, corneal, uveal and iris neovascularization, orbital and eyelid tumors, Stevens Johnson Syndrome, ocular cicatricial pemphigoid, and ocular surface diseases. In some embodiments, the ophthalmological disorder is associated with corneal, retinal, choroidal, uveal, or iris neovascularization. For an ophthalmological disorder, the administering can be, e.g., topical or parenteral administration into the eye, e.g., including, but not limited to, local injection into or near the cornea, retina, vitreous, uvea, orbit, eyelid, conjunctiva, or iris.
- In some embodiments, the disorder is cancer, e.g., as described herein.
- In some embodiments, the subject is selected on the basis that he or she has a disorder associated with neovascularization as described herein.
- In some embodiments, the administering can be, e.g., local or systemic, e.g., parenteral or oral.
- In another aspect, the invention provides methods for identifying candidate therapeutic compounds for the treatment of a disorder associated with neovascularization. The methods include obtaining a sample including a cell that is capable of expressing one or more of the genes listed in Tables 1-6; contacting the sample with the test compound; and evaluating levels, expression, or activity of the gene(s) in the sample, e.g., in the cell. Modulation of levels, expression, or activity of the gene(s) in the sample indicates that the test compound is a candidate therapeutic compound for the treatment of a disorder associated with neovascularization. The levels, expression, or activity of the gene in the sample can be evaluated by methods known in the art, e.g., enzyme assays, immunoassays, high-throughput DNA, RNA, or protein assays, etc. In some embodiments, the gene is ALK1.
- In some embodiments, the method further includes administering the candidate therapeutic compound to an animal model of a disorder associated with neovascularization, and monitoring the animal model for an effect of the candidate therapeutic compound on a parameter of the disorder, e.g., vascularisation, in the animal. A candidate therapeutic compound that causes an improvement in the parameter in the animal model is a candidate therapeutic agent for the treatment of the disorder. In some embodiments, the methods further include administering the candidate therapeutic agent to a subject having the disorder, e.g., a subject in a clinical trial, and monitoring a parameter of the disorder in the subject. A candidate therapeutic agent that improves the parameter in the subject is a therapeutic agent for the treatment of the disorder. In some embodiments, the parameter is visual acuity. In some embodiments, the methods include administering a therapeutically effective amount of the therapeutic agent to a subject in need of treatment for the disorder, thereby treating the disorder.
- In a further aspect, the invention provides methods for identifying candidate compounds, e.g., naturally-occurring compounds, e.g., a polypeptide or biologically active fragment thereof, for the treatment of a disorder associated with neovascularization. The methods include providing a sample including:
-
- (i) cells from a subject, e.g., a human subject, having a disorder associated with blood vessel regression, e.g., retinopathy of prematurity, persistent hyperplastic primary vitreous (PHPV), or retrolental fibroplasia; or
- (ii) cells from a subject, e.g., a human subject, in a stage of development that is associated with vessel regression, e.g., a stage in the development of the hyaloid vascular system;
determining the expression levels of proteins, e.g., one or more, e.g., 2, 3, 5, 10, 15, 20, 25, 30, 50 or 100, of the of the proteins listed in Tables 1-6, in the sample; and comparing the expression levels to a reference, e.g., a sample from an unaffected subject or a subject at a different stage of development associated with blood vessel regression, e.g., a different stage the development of the hyaloid vascular system. A compound that is differentially expressed, e.g., significantly differentially expressed, is a candidate compound for the treatment of a disorder associated with neovascularization.
- In another aspect, the invention includes methods for treating a disorder associated with neovascularization, e.g., an ophthalmological disorder associated with neovascularization as described herein, in a subject by administering a therapeutically effective amount of a therapeutic composition including an activin receptor-like kinase-1 (ALK1) polynucleotide or polypeptide, or an active fragment thereof.
- Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
- Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
-
FIGS. 1A-C . Proteomic analysis of proteins from the lens and vitreous of P1 and P16 mice. The merged image (1A) represents the warped image between P1 (1B) and P16 (1C) obtained with Phoretix 2D evolution software. The proteins excised from 2-D gel (P16) for analysis and identification by mass spectrometry are identified with numbers 1-20 (1C). -
FIGS. 2A-Q . bFGF-pellet induced corneal neovascularization (NV) is inhibited by naked ALK1 DNA injection in vivo. No-pellet controls are shown in 3A-H: Injection of naked DNA [ALK1 (2E-H) and vector only (2A-D)] did not induce corneal NV. The vector plus pellet positive controls are shown in 3I-L: development of NV in the corneal stroma was evident by day 4 (2J); new vessels continued to grow in the direction of the pellet ondays days -
FIG. 3A-B are the amino acid (3A; SEQ ID NO:1) and nucleic acid (3B; SEQ ID NO:2) sequences of human ALK1. - A proteomic approach was used to decipher the biochemical events coexistent with the time points of the progressive regression of the HVS. Reproducible two-dimensional electrophoresis (2-DE) maps were used to study modifications of the protein expression profiles occurring in the mouse lens and vitreous at various stages of the regression of the hyaloid capillaries network. The identity of separated and differentially expressed proteins was confirmed by mass spectrometry (Thermo Electron's Finnigan LCQ Deca XP Plus™ Electrospray ionization (ESI) mass spectrometer).
- In particular, attention was focused on the differential protein expression between
postnatal day 1 andpostnatal day 16. Optical microscopy and hematoxylin-eosin staining studies showed the progressive regression of the hyaloid vascular system of the mouse eye between P1, in which PM, TVL and HV are present and P16, in which these mature capillary structures21 are almost completely regressed. Proteins identified in these screens are targets for therapeutic intervention for the treatment of various disorders associated with neovascularization. Tables 1-6 list proteins which are expected to play a role in vascularisation, inhibition of blood vessel regression, both in the HVS and in other systems, e.g., including pathophysiological processes, and are thus useful in the treatment of disorders associated with neovascularization, as described herein. - TGF-β is a potent inhibitor of vascular endothelial cell proliferation (Lutty et al., (1993), supra). It regulates endothelial proliferation via two receptor/Smad (mother against decapentaplegic) pathways. After ligand binding and activation of Type I receptors, signals are transduced from the membrane to the nucleus via Smads (Seki et al., Circ Res 93, 682-689 (2003)). Type I receptors recruit and phosphorylate Smads, such as Smads2 and 3 by the TβRI/ALK5 type I receptor in response to TGF-β, and Smads1, 5 and 8 by the BMP (bone morphogenetic protein) type I receptors (Feng, Ann. Rev. Cell. Dev. Biol. 659-693 (2005)).
- ALK1 is one of the seven Type I receptors for the TGF-β family of proteins (ten Dijke et al., Science 264, 101-104 (1994); GenelD: 94; GenBank Accession Nos. NM—000020.1 (nucleic acid) and NP—000011.1 (polypeptide)). ALK1 expression has been detected in endothelial cells of highly vascularized tissues (lungs and placenta) (Panchenko et al., Am. J. Physiol. 270, L547-L558 (1996)), normal and neoplastic pituitary cells (Alexander et al., J. Clin. Endocrinol. Metab. 81, 783-790 (1996)), anaplastic large cell lymphoma (Sadahira et al., Pathol. Res. Pract. 195, 657-661 (1999)), inflammatory myofibroblastic tumor (Coffin et al., Mod. Pathol. 14, 569-576 (2001)) and central nervous system cells (Pulford et al., Blood 89, 1394-1404 (1997)). ALK1 transduces the TGF-β1 signal by phosphorylating Smad1, Smad5 or Smad8 (Goumans, et al., EMBO. J. 21, 1743-1753 (2002); Oh et al., Proc. Natl. Acad. Sci. U.S.A. 97, 2626-2631 (2000)). In contrast, ALK5 activates Smads2 and 3 which up-regulate VEGF production (Goumans et al., EMBO J. 21, 1743-1753 (2002)). Upon phosphorylation by the receptors, Smad complexes translocate into the nucleus, where they cooperate with sequence-specific transcription factors at the promoter DNA to regulate gene expression (Feng and Derynck, Annu Rev. Cell. Dev. Biol. 659-693 (2005)). This functional and physical interaction confer both specificity and complexity in transcriptional responses to TGF-β family ligands (Id.).
- Mutations of the ALK1 or endoglin genes have been linked to the human vascular disorder Hereditary Hemorrhagic Telangiectasia (HHT) (Johnson et al., Nat. Genet. 13, 189-195 (1996); McAllister et al., Nat. Genet. 8, 345-351 (1994)). This is an autosomal-dominant disorder, also known as Osler-Rendu-Weber syndrome, characterized by the age-dependent development of focal arteriovenous malformations and telangiectases (Srinivasan et al., Hum. Mol. Genet. 12, 473-482 (2003)).
HHT type 2 is caused by loss of function of the activin receptor-like kinase 1 (ACVRL1 or ALK1) (Id.). The disease is characterized by dilated, thin-walled, vascular anomalies of the skin and mucous membranes and recurrent epistaxis. In the literature, abnormal eye disorders have been documented in 45-65% of patients with HHT, with the most common lesions being conjunctival telangiectasias (Brant et al., Am. J. Ophthalmol. 107, 642-646 (1989); Vase and Vase, Acta. Ophthalmol. Copen. 57, 1084-1090 (1979)). Retinal arteriovenous malformations, retinal telangiectasia and choroidal haemorrhage during intraocular surgery have also been noted (Brant et al., (1989) supra; Mahmoud et al., Am. J. Ophthalmol. 133, 282-284 (2002)). - The sequences of the human ALK1 polypeptide (SEQ ID NO:1) and polynucleotide (SEQ ID NO:2) are shown in
FIG. 3 . Active fragments thereof include, e.g., amino acids 22-503 of SEQ ID NO:1, or nucleotides 346-1791 of SEQ ID NO:2. Active fragments can also include the GS motif, i.e., amino acids 173-202 of SEQ ID NO:1; the Serine/Threonine protein kinases, catalytic domain, i.e., amino acids 204-487 of SEQ ID NO:1; and/or the Activin types I and II receptor domain, i.e., amino acids 19-103 of SEQ ID NO:1. An active fragment retains the ability to block bFGF-induced neovascularization. Homologs of the human ALK1 in other species are known, e.g., for rat, GenBank Accession No. NM—022441.1; for mouse, NM—009612.1 - The polypeptides listed in Tables 1-6, and nucleic acid molecules encoding or inhibiting them, can be incorporated into pharmaceutical compositions as active ingredients. In some embodiments, the pharmaceutical compositions include a human ALK1 polypeptide (e.g., SEQ ID NO:1) or polynucleotide (e.g., SEQ ID NO:2), or an active fragment thereof. In general, it will be preferable to match the composition to the species that is being treated; thus, for example, when treating experimental animals such as mice other species can be used, e.g., from rats or mice.
- Pharmaceutical compositions typically include the active ingredient and a pharmaceutically acceptable carrier. As used herein the language “pharmaceutically acceptable carrier” includes saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds can also be incorporated into the compositions.
- A pharmaceutical composition is typically formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- In some embodiments, the composition is especially adapted for administration into or around the eye. For example, a composition can be adapted to be used as eye drops, or injected into the eye, e.g., using peribulbar or intravitreal injection. Such compositions should be sterile and substantially endotoxin-free, and within an acceptable range of pH. Certain preservatives are thought not to be good for the eye, so that in some embodiments a non-preserved formulation is used. Formulation of eye medications is known in the art, see, e.g., Ocular Therapeutics and Drug Delivery: A Multi-Disciplinary Approach, Reddy, Ed. (CRC Press 1995); Kaur and Kanwar, Drug Dev Ind Pharm. 2002 May; 28(5):473-93; Clinical Ocular Pharmacology, Bartlett et al. (Butterworth-Heinemann; 4th edition (Mar. 15, 2001)); and Ophthalmic Drug Delivery Systems (Drugs and the Pharmaceutical Sciences: a Series of Textbooks and Monographs), Mitra (Marcel Dekker; 2nd Rev&Ex edition (Mar. 1, 2003)).
- Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- Oral compositions generally include an inert diluent or an edible carrier. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules, e.g., gelatin capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer. Such methods include those described in U.S. Pat. No. 6,468,798.
- Administration of a therapeutic composition described herein can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
- The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
- Compositions comprising nucleic acid compounds can also be administered by any method suitable for administration of nucleic acid agents. These methods include gene guns, bio injectors, and skin patches as well as needle-free methods such as the micro-particle DNA vaccine technology disclosed in U.S. Pat. No. 6,194,389, and the mammalian transdermal needle-free vaccination with powder-form vaccine as disclosed in U.S. Pat. No. 6,168,587. Additionally, intranasal delivery is possible, as described in, inter alia, Hamajima et al., Clin. Immunol. Immunopathol., 88(2), 205-10 (1998). Liposomes (e.g., as described in U.S. Pat. No. 6,472,375) and microencapsulation can also be used. Biodegradable targetable microparticle delivery systems can also be used (e.g., as described in U.S. Pat. No. 6,471,996). In some embodiments, the nucleic acid compounds comprise naked DNA, and are administered locally by injection, e.g., as described herein.
- In some embodiments, the compositions are prepared with carriers that will protect the active ingredient against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Such formulations can be prepared using standard techniques. The materials can also be obtained commercially, e.g., from Alza Corporation or Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
- Dosage, toxicity and therapeutic efficacy of the compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds which exhibit high therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
- The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.
- An “effective amount” is an amount sufficient to effect beneficial or desired results. For example, a therapeutic amount is one that achieves a desired therapeutic effect. This amount can be the same or different from a prophylactically effective amount, which is an amount necessary to prevent onset of disease or disease symptoms. An effective amount can be administered in one or more administrations, applications or dosages. A therapeutically effective amount of a composition depends on the composition selected. The compositions can be administered one from one or more times per day to one or more times per week; including once every other day. The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of the compositions of the invention can include a single treatment or a series of treatments.
- The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.
- Nucleic Acids for Expression
- The therapeutic compositions described herein can include nucleic acid molecules encoding a selected protein, e.g., a protein listed in one of Tables 1-6, e.g., ALK1; these are useful, e.g., where an increase in the expression and/or activity of a selected protein is desirable. Nucleic acid molecules comprising expression constructs can be used, e.g., for in vivo or in vitro expression of a selected protein. In some embodiments, expression can be restricted to a particular cell types so as to reconstitute the function of the selected protein in a cell, e.g., a cell in which that polypeptide is misexpressed, or in which expression of that polypeptide would produce a therapeutic benefit.
- A nucleic acid encoding the selected protein can be inserted in an expression vector, to make an expression construct. A number of suitable vectors are known in the art, e.g., viral vectors including recombinant retroviruses, adenovirus, adeno-associated virus, and herpes simplex virus-1, adenovirus-derived vectors, or recombinant bacterial or eukaryotic plasmids. For example, the expression construct can include: a coding region; a promoter sequence, e.g., a promoter sequence that restricts expression to a selected cell type, a conditional promoter, or a strong general promoter; an enhancer sequence; untranslated regulatory sequences, e.g., a 5′ untranslated region (UTR), a 3′UTR; a polyadenylation site; and/or an insulator sequence. Such sequences are known in the art, and the skilled artisan would be able to select suitable sequences. See, e.g., Current Protocols in Molecular Biology, Ausubel, F. M. et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14, and other standard laboratory manuals.
- Expression constructs can be administered in any biologically effective carrier, e.g. any formulation or composition capable of effectively delivering the component gene to cells in vivo. Viral vectors transfect cells directly; plasmid DNA can be delivered with the help of, for example, cationic liposomes (e.g., Lipofectin) or derivatized (e.g. antibody conjugated), polylysine conjugates, gramicidin S, artificial viral envelopes or other such intracellular carriers, as well as direct injection of the gene construct or CaPO4 precipitation. In some embodiments, the nucleic acid is applied “naked” to a cell, i.e., is applied in a simple buffer without the use of any additional agents to enhance uptake. See, e.g., Current Protocols in Molecular Biology, Ausubel, F. M. et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard laboratory manuals.
- In clinical settings, the nucleic acids can be introduced into a subject by any of a number of methods, each of which is familiar in the art. For instance, a pharmaceutical preparation of the gene delivery system can be introduced systemically, e.g. by intravenous injection, and specific transduction of the protein in the target cells occurs predominantly from specificity of transfection provided by a targeted gene delivery vehicle, cell-type or tissue-type expression due to the transcriptional regulatory sequences controlling expression of the receptor gene, or a combination thereof. In other embodiments, initial delivery of the recombinant gene is more limited with introduction into the animal being quite localized. For example, the gene delivery vehicle can be introduced by catheter (see U.S. Pat. No. 5,328,470) or by stereotactic injection (e.g. Chen et al. (1994) PNAS 91: 3054-3057).
- Inhibitory Nucleic Acid Molecules
- The therapeutic compositions described herein can include inhibitory nucleic acid molecules that are targeted to a selected target RNA encoding a protein listed in one of Tables 1-6, e.g., antisense, siRNA, ribozymes, and aptamers; these are useful, e.g., where a decrease in the expression and/or activity of a target protein is desirable. Based upon sequences known in the art, one of skill in the art can easily choose and synthesize any of a number of appropriate inhibitory nucleic acid molecules for use in accordance with the present invention. For example, a “gene walk” comprising a series of oligonucleotides of 15-30 nucleotides spanning the length of a target nucleic acid can be prepared, followed by testing for inhibition of target gene expression, to provide an antisense sequence. Optionally, gaps of 5-10 nucleotides can be left between the oligonucleotides to reduce the number of oligonucleotides synthesized and tested. Similar methods can be used to generate siRNAs, aptamers, and ribozymes
- siRNA Molecules
- RNAi is a process whereby double-stranded RNA (dsRNA, also referred to herein as si RNAs or ds siRNAs, for double-stranded small interfering RNAs,) induces the sequence-specific degradation of homologous mRNA in animals and plant cells (Hutvagner and Zamore, Curr. Opin. Genet. Dev.:12, 225-232 (2002); Sharp, Genes Dev., 15:485-490 (2001)). In mammalian cells, RNAi can be triggered by 21-nucleotide (nt) duplexes of small interfering RNA (siRNA) (Chiu et al., Mol. Cell. 10:549-561 (2002); Elbashir et al., Nature 411:494-498 (2001)), or by micro-RNAs (miRNA), functional small-hairpin RNA (shRNA), or other dsRNAs which are expressed in vivo using DNA templates with RNA polymerase III promoters (Zeng et al., Mol. Cell. 9:1327-1333 (2002); Paddison et al., Genes Dev. 16:948-958 (2002); Lee et al., Nature Biotechnol. 20:500-505 (2002); Paul et al., Nature Biotechnol. 20:505-508 (2002); Tuschl, T., Nature Biotechnol. 20:440-448 (2002); Yu et al., Proc. Natl. Acad. Sci. USA 99(9):6047-6052 (2002); McManus et al., RNA 8:842-850 (2002); Sui et al., Proc. Natl. Acad. Sci. USA 99(6):5515-5520 (2002).)
- The nucleic acid molecules or constructs can include dsRNA molecules comprising 16-30, e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in each strand, wherein one of the strands is substantially identical, e.g., at least 80% (or more, e.g., 85%, 90%, 95%, or 100%) identical, e.g., having 3, 2, 1, or 0 mismatched nucleotide(s), to a target region in the mRNA, and the other strand is complementary to the first strand. The dsRNA molecules can be chemically synthesized, or can transcribed be in vitro from a DNA template, or in vivo from, e.g., shRNA. The dsRNA molecules can be designed using any method known in the art; a number of algorithms are known, and are commercially available. Gene walk methods can be used to optimize the inhibitory activity of the siRNA.
- The inhibitory nucleic acid compositions can include both siRNA and modified siRNA derivatives, e.g., siRNAs modified to alter a property such as the pharmacokinetics of the composition, for example, to increase half-life in the body, as well as engineered RNAi precursors.
- siRNAs can be delivered into cells by methods known in the art, e.g., cationic liposome transfection and electroporation. siRNA duplexes can be expressed within cells from engineered RNAi precursors, e.g., recombinant DNA constructs using mammalian Pol III promoter systems (e.g., H1 or U6/snRNA promoter systems (Tuschl (2002), supra) capable of expressing functional double-stranded siRNAs; (Bagella et al., J. Cell. Physiol. 177:206-213 (1998); Lee et al. (2002), supra; Miyagishi et al. (2002), supra; Paul et al. (2002), supra; Yu et al. (2002), supra; Sui et al. (2002), supra). Transcriptional termination by RNA Pol III occurs at runs of four consecutive T residues in the DNA template, providing a mechanism to end the siRNA transcript at a specific sequence. The siRNA is complementary to the sequence of the target gene in 5′-3′ and 3′-5′ orientations, and the two strands of the siRNA can be expressed in the same construct or in separate constructs. Hairpin siRNAs, driven by H1 or U6 snRNA promoter and expressed in cells, can inhibit target gene expression (Bagella et al. (1998), supra; Lee et al. (2002), supra; Miyagishi et al. (2002), supra; Paul et al. (2002), supra; Yu et al. (2002), supra; Sui et al. (2002) supra). Constructs containing siRNA sequence under the control of T7 promoter also make functional siRNAs when cotransfected into the cells with a vector expression T7 RNA polymerase (Jacque (2002), supra).
- Antisense
- An “antisense” nucleic acid can include a nucleotide sequence that is complementary to a “sense” nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to a TEF mRNA sequence. The antisense nucleic acid can be complementary to an entire coding strand of a target sequence, or to only a portion thereof. In another embodiment, the antisense nucleic acid molecule is antisense to a “noncoding region” of the coding strand of a nucleotide sequence (e.g., the 5′ and 3′ untranslated regions).
- An antisense nucleic acid can be designed such that it is complementary to the entire coding region of a target mRNA, but can also be an oligonucleotide that is antisense to only a portion of the coding or noncoding region of the target mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of the target mRNA, e.g., between the −10 and +10 regions of the target gene nucleotide sequence of interest. An antisense oligonucleotide can be, for example, about 7, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, or more nucleotides in length.
- An antisense nucleic acid can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. The antisense nucleic acid also can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).
- In some embodiments, the antisense nucleic acid molecule is an V-anomeric nucleic acid molecule. An V-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual (3-units, the strands run parallel to each other (Gaultier et al., Nucleic Acids. Res. 15:6625-6641 (1987)). The antisense nucleic acid molecule can also comprise a 2′-o-methylribonucleotide (Inoue et al. Nucleic Acids Res. 15:6131-6148 (1987)) or a chimeric RNA-DNA analogue (Inoue et al. FEBS Lett., 215:327-330 (1987)).
- In some embodiments, the antisense nucleic acid is a morpholino oligonucleotide (see, e.g., Heasman, Dev. Biol. 243:209-14 (2002); Iversen, Curr. Opin. Mol. Ther. 3:235-8 (2001); Summerton, Biochim. Biophys. Acta. 1489:141-58 (1999).
- Target gene expression can be inhibited by targeting nucleotide sequences complementary to a regulatory region (e.g., promoters and/or enhancers) to form triple helical structures that prevent transcription of the SptS gene in target cells. See generally, Helene, Anticancer Drug Des. 6:569-84 (1991); Helene, Ann. N.Y. Acad. Sci. 660:27-36 (1992); and Maher, Bioassays 14:807-15 (1992). The potential sequences that can be targeted for triple helix formation can be increased by creating a so called “switchback” nucleic acid molecule. Switchback molecules are synthesized in an alternating 5′-3′,3′-5′ manner, such that they base pair with first one strand of a duplex and then the other, eliminating the necessity for a sizeable stretch of either purines or pyrimidines to be present on one strand of a duplex.
- Ribozymes
- Ribozymes are a type of RNA that can be engineered to enzymatically cleave and inactivate other RNA targets in a specific, sequence-dependent fashion. By cleaving the target RNA, ribozymes inhibit translation, thus preventing the expression of the target gene. Ribozymes can be chemically synthesized in the laboratory and structurally modified to increase their stability and catalytic activity using methods known in the art. Alternatively, ribozyme genes can be introduced into cells through gene-delivery mechanisms known in the art. A ribozyme having specificity for a target nucleic acid can include one or more sequences complementary to the nucleotide sequence of a cDNA encoding a protein described herein, and a sequence having known catalytic sequence responsible for mRNA cleavage (see U.S. Pat. No. 5,093,246 or Haselhoff and Gerlach Nature 334:585-591 (1988)). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a target mRNA. See, e.g., Cech et al. U.S. Pat. No. 4,987,071; and Cech et al. U.S. Pat. No. 5,116,742. Alternatively, a target mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel and Szostak, Science 261:1411-1418 (1993).
- Administration of Nucleic Acid Molecules
- The nucleic acid molecules described herein can be administered to a subject (e.g., by direct injection at a tissue site), or generated in situ. For example, inhibitory nucleic acid molecules can be administered such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a target protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. Nucleic acid molecules that encode an active agent are generally administered such that they enter a cell and are expressed therein.
- In some embodiments, the nucleic acid molecules can be administered selectively, e.g., by local injection, or modified to target selected cells (e.g., by the use of a tissue-specific promoter) and then administered systemically. For systemic administration, nucleic acid molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the nucleic acid nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens. The nucleic acid nucleic acid molecules can also be delivered to cells using vectors known in the art, e.g., as described herein. To achieve sufficient intracellular concentrations of the inhibitory nucleic acid molecules, vector constructs in which the inhibitory nucleic acid nucleic acid molecule is placed under the control of a promoter, e.g., a strong promoter can be used. Methods for creating suitable vectors, and choosing promoters, are known in the art.
- Methods of Treatment
- The polypeptides and nucleic acids described herein, e.g., ALK1 polypeptides (e.g., SEQ ID NO:1) or polynucleotides (e.g., SEQ ID NO:2), and active fragments thereof, are useful in the treatment of disorders associated with neovascularization, i.e., abnormal angiogenic processes, e.g., disorders in the formation of blood vessels. Typically, the disorder will stem from overformation of blood vessels, or formation of blood vessels in an unwanted area, e.g., in the avascular regions of the eye, e.g., retinopathies, or in a tumor, e.g., a cancerous or benign tumor. For example, the ophthalmological disorder can be age-related macular degeneration, where new blood vessels grow under the retina, or diabetic retinopathy, where abnormal vessels grow on top of the retina. Other ophthalmological disorders include retinopathy of prematurity, corneal graft rejection, glaucoma, herpetic and infectious keratitis, ocular ischemia, neovascular glaucoma, corneal, uveal and iris neovascularization, orbital and eyelid tumors, Stevens Johnson Syndrome, ocular cicatricial pemphigoid, wounds, and ocular surface diseases. The disorder can be characterized by, for example, corneal, retinal, choroidal, uveal, or iris neovascularization
- The disorder may stem from the formation of blood vessels that deliver blood to a tissue, e.g., a primary or metastatic cancerous or benign tumors, e.g., cancer. A metastatic tumor can arise from a multitude of primary tumor types, including but not limited to those of prostate, colon, lung, breast and liver origin.
- As used herein, the terms “cancer,” “hyperproliferative,” and “neoplastic” refer to cells having the capacity for autonomous growth, i.e., an abnormal state or condition characterized by rapidly proliferating cell growth. Hyperproliferative and neoplastic disease states may be categorized as pathologic, i.e., characterizing or constituting a disease state, or may be categorized as non-pathologic, i.e., a deviation from normal but not associated with a disease state. The term is meant to include all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness. “Pathologic hyperproliferative” cells occur in disease states characterized by malignant tumor growth. Examples of non-pathologic hyperproliferative cells include proliferation of cells associated with wound repair; thus, the methods include administration of a compound identified by a method described herein to maintain avascularity during wound healing. In this embodiment, the ophthalmological disorder is a wound, including both accidental as well as intentional wounds (e.g., surgical wounds).
- In some embodiments, the ophthalmological disorder is a cancer of the eye, e.g., eyelid tumors, e.g., malignant eye lid tumors, benign eye lid tumors, basal cell carcinoma, squamous cell carcinoma, sebaceous cell carcinoma, and malignant melanoma; conjunctival tumors, e.g., pigmented conjunctival tumors, melanoma and primary acquired melanosis with atypia, squamous conjunctival neoplasia, conjunctival lymphoma, and Kaposi's Sarcoma; iris tumors, e.g., iris melanoma, iris pigment epithelial cyst, anterior uveal metastasis, and pearl cyst of the iris; infiltrative intraocular tumors, e.g., multiple myeloma, lymphoma, and leukemia; choroidal tumors, e.g., choroidal melanoma, choroidal metastasis, choroidal nevus, choroidal hemangioma, choroidal osteoma, and Nevus of Ota; retinal tumors, e.g., retinoblastoma, retinal pigment epithelial tumors, retinal pigment epithelial hypertrophy, von Hippel angioma; optic nerve tumors, e.g., melanocytoma, melanoma, meningioma, circumpapillary metastasis; orbital tumors, e.g., lymphangioma, cavernous hemangioma, meningioma, mucocele, rhabdomyosarcoma, orbital pseudotumor, adenoid cystic carcinoma, periocular hemangioma of childhood; cancers of the ocular adnexa, e.g., lacrimal gland carcinomas such as adenoid cystic carcinoma and mucoepidermal epithelioma; and metastatic ocular tumors, e.g., metastatic choroidal melanoma, and metastatic retinoblastoma.
- As used in this context, to “treat” means to ameliorate at least one symptom associated with abnormal angiogenesis as well as reduce neovascularization. For the treatment of cancers and solid tumors, to “treat” includes inhibition of the growth of blood vessels resulting in a lack of nutrients for the tumors and/or cancer cells needed by the tumor for its growth. Tumors and growths will decrease in size and possibly disappear. Administration of a therapeutically effective amount of a composition for the treatment of arthritic conditions will result in decreased blood vessel formation in cartilage, specifically joints, resulting in increased mobility and flexibility in these regions. In ophthalmologic conditions, administration of a therapeutically effective amount of a composition described herein will reduce the formation of extraneous blood vessels in the retina, resulting in unobstructed or less obstructed vision. In the treatment of disorders such as cancer, administration of a therapeutically effective amount of a composition described herein will inhibit the growth and/or further formation of blood vessels, thereby inhibiting the formation of any lesions and/or tumors that arise.
- The invention includes methods for screening test compounds, e.g., polypeptides, polynucleotides, inorganic or organic large or small molecule test compounds, to identify agents useful in the treatment of disorders associated with neovascularization, e.g., as described herein.
- As used herein, “small molecules” refers to small organic or inorganic molecules of molecular weight below about 3,000 Daltons. In general, small molecules useful for the invention have a molecular weight of less than 3,000 Daltons (Da). The small molecules can be, e.g., from at least about 100 Da to about 3,000 Da (e.g., between about 100 to about 3,000 Da, about 100 to about 2500 Da, about 100 to about 2,000 Da, about 100 to about 1,750 Da, about 100 to about 1,500 Da, about 100 to about 1,250 Da, about 100 to about 1,000 Da, about 100 to about 750 Da, about 100 to about 500 Da, about 200 to about 1500, about 500 to about 1000, about 300 to about 1000 Da, or about 100 to about 250 Da).
- The test compounds can be natural products or members of a combinatorial chemistry library. A set of diverse molecules can be used to cover a variety of functions such as charge, aromaticity, hydrogen bonding, flexibility, size, length of side chain, hydrophobicity, and rigidity. Combinatorial techniques suitable for synthesizing small molecules are known in the art, e.g., as exemplified by Obrecht and Villalgordo, Solid-Supported Combinatorial and Parallel Synthesis of Small-Molecular-Weight Compound Libraries, Pergamon-Elsevier Science Limited (1998), and include those such as the “split and pool” or “parallel” synthesis techniques, solid-phase and solution-phase techniques, and encoding techniques (see, for example, Czarnik, Curr. Opin. Chem. Bio. 1:60-6 (1997)). In addition, a number of libraries, e.g., small molecule libraries, are commercially available. A number of suitable small molecule test compounds are listed in U.S. Pat. No. 6,503,713, incorporated herein by reference in its entirety.
- Libraries screened using the methods of the present invention can comprise a variety of types of test compounds. A given library can comprise a set of structurally related or unrelated test compounds. In some embodiments, the test compounds are peptides or peptidomimetic molecules. In some embodiments, the test compounds are nucleic acids, e.g., antisense, RNAi, or aptamers.
- In some embodiments, the test compounds and libraries thereof can be obtained by systematically altering the structure of a first test compound, e.g., a first test compound that is structurally similar to a known natural binding partner of the target polypeptide, or a first small molecule identified as capable of binding the target polypeptide, e.g., using methods known in the art or the methods described herein, and correlating that structure to a resulting biological activity, e.g., a structure-activity relationship study. As one of skill in the art will appreciate, there are a variety of standard methods for creating such a structure-activity relationship. Thus, in some instances, the work may be largely empirical, and in others, the three-dimensional structure of an endogenous polypeptide or portion thereof can be used as a starting point for the rational design of a small molecule compound or compounds. For example, in one embodiment, a general library of small molecules is screened, e.g., using the methods described herein.
- In some embodiments, a test compound is applied to a test sample, e.g., a cell or living tissue or organ, e.g., an eye, and one or more effects of the test compound is evaluated. In a cultured or primary cell for example, the ability of the test compound to modulate expression of one or more of the proteins listed in Tables 1-6 can be evaluated. In the eye, for example, the ability of the test compounds to modulate expression of one or more of the proteins listed in Tables 1-6 can be evaluated. Methods for evaluating each of these effects are known in the art. For example, ability to modulate expression of a protein can be evaluated at the gene or protein level, e.g., using quantitative PCR or immunoassay methods. In some embodiments, high throughput methods, e.g., protein or gene chips as are known in the art (see, e.g., Ch. 12, Genomics, in Griffiths et al., Eds., Modern Genetic Analysis, 1999, W. H. Freeman and Company; Ekins and Chu, Trends in Biotechnology, 1999, 17:217-218; MacBeath and Schreiber, Science 2000, 289(5485):1760-1763; Simpson, Proteins and Proteomics: A Laboratory Manual, Cold Spring Harbor Laboratory Press; 2002; Hardiman, Microarrays Methods and Applications: Nuts & Bolts, DNA Press, 2003), can be used to detect an effect on two, three, four, five or more of the proteins listed in Tables 1-6.
- Compounds identified as “hits” (e.g., test compounds that demonstrate an ability to modulate, i.e., cause an increase or decrease in levels, expression, or activity, of one or more of the proteins listed in Tables 1-6) in the first screen can be selected and systematically altered, e.g., using rational design, to optimize binding affinity, avidity, specificity, or other parameter. Such optimization can also be screened for using the methods described herein. Thus, in one embodiment, the invention includes screening a first library of small molecules using a method known in the art and/or described herein, identifying one or more hits in that library, subjecting those hits to systematic structural alteration to create a second libraries of compounds structurally related to the hit, and screening the second library using the methods described herein.
- Small molecules identified as hits can be considered candidate therapeutic compounds, useful in treating disorders associated with neovascularization, as described herein. A variety of techniques useful for determining the structures of “hits” can be used in the methods described herein, e.g., NMR, mass spectrometry, gas chromatography equipped with electron capture detectors, fluorescence and absorption spectroscopy. Thus, the invention also includes compounds identified as “hits” by the methods described herein, and methods for their administration and use in the treatment, prevention, or delay of development or progression of a disorder described herein.
- Test compounds identified as candidate therapeutic compounds can be further screened by administration to an animal model of a disorders associated with neovascularization, as described herein. The animal can be monitored for a change in the disorder, e.g., for an improvement in a parameter of the disorder, e.g., a parameter related to clinical outcome. In some embodiments, the parameter is unwanted vascularisation, and an improvement would be a decrease in the levels of vascularisation.
- One of skill in the art will appreciate that the methods described herein can be performed on non-rodent, e.g., human samples, e.g., samples obtained from human fetuses at different stages of development, as well as samples at substantially the same stage of development, but in pathological and non-pathological stages. For example, a surgical specimen from a subject with a disorder, e.g., retinopathy of prematurity or retrolental fibroplasias, can be used, and compared with a normal, unaffected control, e.g., an age-matched control.
- The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.
- To document the changes in the hyaloid vascular system associated with development in the cornea, whole-mount specimens were observed.
- A total of 44 C57BL/6 newborn male and female litters were obtained from Jackson Laboratories (Bar Harbor, Me.) were used for the experiments described herein. The age of the newborn mice was expressed in terms of post-gestational days. The newborn mice were sacrificed on
post-gestational days P 1 mice, 20 eyes ofP 4 mice, 12 eyes of P 8 mice and 12 eyes ofP 16 mice. Each of the 12 newborn mice used for the histological study was perfused with 4% paraformaldehyde in PBS under general anesthesia administered by intramuscular injection of a mixture of ketamine (200 mg/kg) and xylazine (10 mg/kg). The eyes were removed and immerse in buffered neutral formalin solution (100 ml 40% formalin, 900 ml distilled water, 4.0 gm monobasic sodium phosphate, 6.5 gm dibasic sodium phosphate), then they were embedded into paraffin and were cut in tissue slices of 5 micron each with a microkeratome. Each sample was stained with Hematoxylin-Eosin (H-E) staining - By embryonic day 11 (E11) the hyaloid artery enters the optic cup and extends anteriorly, branching to form the vascular tunic of the lens (Smith, Systematic evaluation of the Mouse Eye: Anatomy, Pathology, and Biomethods. Pp 45-63. Sunders, 2002). From E14 to birthday the blood vessels that occupied most of the vitreous cavity in earlier stages have become less prominent except around the lens and along the inner retinal surface; the PM and the TVL remain prominent (Smith, Systematic evaluation of the Mouse Eye: Anatomy, Pathology, and Biomethods. Pp 45-63. Sunders, 2002).
- PM
- The PM of the newborn mice showed as a dense plexus of capillaries that began to regress on
post-gestation day 4 and become vestigial on day 8. The PM disappeared completely in all eyes onday 16. - TVL
- The radial branches of the TVL that lie on the lens surface are prominent until P4, particularly posterior to the lens equator. Later there is a gradual disappearance of the TVL and it is completely disappeared in about one third of eyes examined on day P24 and in all eyes on day P30.
- HA and VHP
- The HA arose from the optic disc as a single thick proximal trunk and entered the vitreous branching in several vessels of the VHP and running anteriorly to the posterior pole of the lens. As the whole eye developed in size and the volume of the vitreous increased, the VHP run toward the lens joining the TVL and became less prominent. Involution of HA and VHP has begun by
day 1 and fromday 12 to day 30 there is a gradual disappearance of those vessels. - These results concur with previous reports of HVS development and regression.
- This example describes the use of a proteomic approach to try to decipher the biochemical events coexisting with the progressive regression of the HVS. The proteomic analysis provided an opportunity to compare different stages of the mouse eye development, to identify specific qualitative and quantitative protein changes, associated with the early maintenance and later regression of the HVS.
- Therefore to fully characterize and analyze such a dynamic process, experiments should be performed that capture the protein expression profiles of the lens and the vitreous at the various stages of blood vessel regression.
- To prepare mouse lens and vitreous for 2-D electrophoresis, 32 newborn mice were decapitated. The eyes were enucleated and then frozen at −80 degrees Celsius. The frozen eyes were scraped with a blade to remove cornea, aqueous humor, conjunctiva, sclera, iris, ciliary body, uvea and retina and to obtain the lens surrounded by PM and TVL and the primary vitreous containing VHP.
- The scraping was done on a dry-ice bed to prevent the specimen from warming up and the consequent protein denaturation, melting of the tissue and contamination of the specimen by eye components different from lens and primary vitreous.
- Twenty specimens of P1, 20 specimens of P4, 12 specimens of P8, and 12 specimens of P16 were independently solubilized in 250 μl of Total Protein Extraction Buffer (7 M urea, 2 M thiourea, 1% (w/v) ASB-14 detergent, 40 mM Tris base, 0.001% bromophenol blue, 20% carrier ampholyte; Biorad Laboratories, Hercules, Calif.) plus 2 μl of 200 mM tributylphosphine by mechanically homogenizing them with an electrical tissue homogenizer for 5 minutes, in an ice-water bath to prevent the specimens from warming up.
- The homogenate was transferred into 1.5 ml micro centrifuge tubes and the protein extracts were cleared by centrifugation at 14,000 rpm for 20 minutes at 4° Celsius to remove particulates. The protein concentration of the cleared supernatants was determined by using a compatible protein assay (Biorad Laboratories, Hercules, Calif.), and samples were stored at −80° Celsius until use.
- Three separate experiments were performed.
- I. Differential Protein Expression in P1, P4, P8, P16 using IPG Strips pH 3-10
- A time course experiment was designed to examine the changes in protein expression at the critical time points throughout the HVS regression process.
- Lens and vitreous of P1, P4, P8 and P16 were selected to perform the experiment because the histological analysis showed that in
post-gestation day 1 the hyaloid network is still prominent and bypost-gestational day 16 the hyaloid network is already vestigial. In this experiment, three samples per each post-gestational day were loaded onto nonlinear immobilized pH gradient (IPG) gel strips (7 cm, pH 3-10) and rehydrated overnight with Rehydration/Sample Buffer (Biorad Laboratories, Hercules, Calif.). - As this is the first reported application of proteome analysis on HVS regression, several of the conditions for tissue selection and preparation were developed and optimized to obtain clean specimen of lens and vitreous to avoid the presence of proteins coming from other part of the eye on the final 2-DE gels.
- Images of the 2-DE gels were captured with Molecular Imager FX Pro Plus multi-imager system and protein expression profile at each time point was compared in triplicate using the Phoretix 2D imaging analysis software.
- Protein spots that were reproducibly differentially expressed in P1 and
P 16 were considered for protein identification. The statistical significance of changes was evaluated using the Phoretix 2D software. - Gel bands were excised and minced into approximate 1 mm3 pieces with a sterile razor blade of the Xcise technology platform from Proteome system and placed into a sterile microcentrifuge. Gel pieces were destained 3 times by adding 200 uL of 25 mM NH4HCO3 in 50% acetonitrile, dried using a SpeedVac® concentrator, alkylated and digested with trypsin (Promega, Madison, Wis., USA) in 50 mM of ammonium bicarbonate overnight to release tryptic peptides. Samples were dried in a SpeedVac® to remove residual ammonium bicarbonate. Peptides were resuspended in 50% acetonitrile with 1% formic acid solution. About 30% of the digest was subjected to nano-LC ESI IT MS/MS analysis.
- A Surveyor LC pump (ThermoElectron, CA) with a C18 trapping column (300 um i.d.×1 mm, Dionex, CA) and a self-packed reversed-phase column 75 mm i.d.×15 cm (Magic C18AQ, 3 um) was used for nano-LC experiments. An LCQ Deca XP Plus ESI mass spectrometer (Thermo Electron, CA) was used for all the experiments. In data-dependent MS/MS scanning, a full MS scan between 400 and 2000 m/z was followed by five full MS/MS scans for the five most intense ions from the MS scan in all ESI. MS/MS data-dependent acquisition, followed by database searching with SEQUEST (BioWorks 3.1, ThermoElectron) allowed protein identification.
- Fully tryptic peptides were matched with SEQUEST at a delta correlation ( )Cn) of greater than 0.08 and correlation (Xcorr) greater than 1.9, 2.2 and 3.5 for charged states of +1, +2 and +3, respectively. The search was performed against the whole NCBInr mouse protein sequence database, and human homologs (e.g., proteins with at least 75% identity to the mouse sequence) were identified (www.ncbi.nml.nih.gov).
- Protein expression maps were generated in triplicate per each time point obtaining a reproducible separation of the protein spots on the 2-DE gels. On average, up to 1300 proteins spots could be detected in each gel with the Phoretix 2D imaging analysis software. This software provides the ability to “warp” different gel images using mathematical algorithms, improving the quality of the protein spot matching between the gels and allowing easy detection of the differences among the gels.
- The 2-DE gels demonstrated a progressive lessening in the number and in the intensity of the protein spots from P1 to P16, particularly of the proteins that migrated in the area corresponding to
pI 4 topI 7 and Mr 30 kDa to 90 kDa. However, the warping of P1, P4 and P8 with P16 revealed the presence of 20 protein spots in P16 that are not present in the other gels. - This evidence suggest the presence in the earlier post-gestation days of an active protein expression coexisting with the presence of a prominent HVS and the presence in P16 of factors whose synthesis or degradation is related to the regression of the HVS itself.
- For this initial study, 11 protein spots were identified, using the Phoretix 2D imaging analysis software, that were present in P1 at greater than two-fold higher levels of expression relative to P16 were selected and excised for identification. From these 11 spots, 23 differentially expressed proteins were identified (Table 1); one of them is an unnamed protein product and two of them (the serotransferrin precursor and similar to ethanol induced 6) were identified in multiple spots, as they are post-translationally modified versions of the same protein.
-
TABLE 1 Proteins Present in P1 at >2X levels of expression in P16 HUMAN MOUSE HOMOLOG GENE GENE # PROTEIN BANK # BANK # 1. alpha fetoprotein 31982513 120042 2. Calmodulin 115512 56404656 3. protein product 19263784 19263784 (—) 4. Creatine kinase 15929689 34335231 5. dermatan-4-sulfotransferase-1 31980715 18497304 6. Ethanol induced 6 homolog 38082607 (—) 7. GRP1 (general receptor for 31980946 32171221 phosphoinositides 1) 8. heterogeneous nuclear ribonucleoprotein K 38074994 51464712 homolog 9. histidine triad nucleotide binding protein 33468857 21359982 10. immunoglobulin 9E10 heavy chain 2505942 (—) 11. KH-type splicing regulatory protein 38082738 4808586 12. Profilin 112846944 4826898 13. prolyl 4-hydroxylase, beta polypeptide 20913929 20070125 14. protein 40 kD homolog 38079048 51460993 15. protein product 33115175 33115175 (—) 16. protein product 12845853 12845853 (—) 17. RAD23a homolog 38089412 (—) 18. Ribosomal protein S12 17390846 (—) 19. ring finger and WD repeat domain 124418905 50233824 20. Serotransferrin precursor 21363012 136191 21. Synovial sarcoma, X breakpoint 221594537 41281571 interacting protein 22. Trk-fused gene 19353070 21361320 23. Tumor rejection antigen gp96 15030324 4507677 - All 20 of the spots differentially expressed in P16, i.e., present in P16 at greater than two-fold higher levels of expression relative to P1 were excised and identified. From these 20 spots, 39 differentially expressed proteins were identified (Table 2); four of them are unnamed protein products and eight of them (Crybbl protein, fatty acid binding protein 5, crystallin α1, crystallin βA1, crystallin βA4, crystallin βB3, crystalline γb, and crystalline γd) were identified in different spots, as they represented modified versions or fragments of the same protein.
-
TABLE 2 Proteins Present in P16 at >2X levels of expression in P1 HUMAN MOUSE HOMOLOG GENE GENE # PROTEIN BANK # BANK # 1. protein product 38089687 38089687 (—) 2. Acvrl1 protein (ALK1) 15929282 4557243 3. Albumin 119353306 8392890 4. Alpha enolase 13637776 4433141 5. Cathepsin 3 precursor19424144 (—) 6. Cofilin 137194891 5031635 7. Crybb1 protein 22137737 47678381 8. Crystallin, alpha A 30794510 (—) 9. Crystallin, beta A1 20304089 12056461 10. Crystallin, beta A2 31088965 13623372 11. Crystallin, beta A4 33989574 4503059 12. Crystallin, beta B2 6681035 4503063 13. Crystallin, beta B3 37589234 4758074 14. Crystallin, gamma B 38049551 4885157 15. Crystallin, gamma C 33990600 10518338 16. Crystallin, gamma D 34784220 13377002 17. Crystallin, gamma F 33991687 (—) 18. Cytochrome P450 2D9 homolog 38077646 (—) 19. Enolase 315488630 16554592 20. Fatty acid binding protein 5 6754450 30583736 21. FX3B_MOUSE F-box/LRR-repeat 37537783 (—) protein 3B 22. Glyceraldehyde-3-phosphate 6679939 19924131 dehydrogenase 23. Guanine nucleotide-binding protein 15341782 20357526 24. Heat shock 70 kD protein 5 29748016 24234686 25. Heat shock cognate 71 kDa protein 123651 123648 26. Hspb1 protein 17390597 4504517 27. IgM heavy chain 1763745 54780866 28. keratin 5b homolog 38077186 (—) 29. keratin complex 2, basic, gene 520911031 (—) 30. Knsl7 protein 38173736 9910266 31. protein product mKIAA0585 protein 28972291 (—) 32. protein product mKIAA0650 protein 37360026 (—) 33. protein kinase, cAMP dependent 31543509 38257138 regulatory 34. protein product 1333921 1333921 (—) 35. protein product 26335149 26335149 (—) 36. RAD50 homolog 6679609 19924130 37. Solute carrier family 20 28204938 58761541 38. Tubulin 33416314 34784746 39. Vimentin 31982755 57471648
II. Differential Protein Expression in P4 and P16 using IPG strips pH 4-7,5-8, 7-10 - The use of broad range strips allows the display of the most proteins in a single gel. With narrow-range and micro-range overlapping gradient strips, resolution is increased by expanding a small pH range across the entire width of a gel and more spots can be displayed per each sample. This is due to the extra resolving power from use of a narrower pI range per gel. Because proteins outside of the pH range of the strip are excluded, more total protein mass can be loaded per strip, allowing more proteins to be detectable.
- In this experiment, three samples for P4 and three samples for P16 were loaded onto nonlinear immobilized pH gradient (IPG) 7 cm gel strips with pH 4-7, pH 5-8, pH 7-10 and rehydrated overnight with Rehydration/Sample Buffer. Isoelectric focusing (IEF) was performed with a programmed voltage gradient at 8,000 V for 5 hours.
- IPG strips were prepared for the second dimension by two sequential 10 minute incubations in 6 M urea, 50 mM Tris (pH 8.8), 30% glycerol, 2% SDS, and 0.001% bromophenol blue, containing, alternately, 2% DTT or 2.5% iodoacetamide.
- Following equilibration, second-dimension separation was then performed on 4-20% SDS-PAGE gels (Biorad Laboratories, Hercules Calif.) with the first-dimension IPG strip embedded in 0.5% agarose at the top. Proteins on gel were fixed in 10% acetic acid and 20% methanol for 1 hour and were then stained using SYPRO Rubin Protein Gel stain (Biorad Laboratories, Hercules Calif.). In total, 12 gels with samples were prepared and subjected to analysis for the first experiment and 6 for the second experiment.
- Using the Phoretix 2D imaging analysis software, the gels were warped the P4 map was matched with the P16 map to compare and identify proteins that were differentially expression in these gels. Of the proteins with differential expression, a number of spots were selected.
- Comparing P4 map pH 4-7 with P16 map pH 4-7, fifteen spots were selected that included proteins that were differentially expressed found to be clearly present in P4 and barely detectable or not detectable in P16, and another fifteen spots that were clearly present in P16 and barely detectable or not detectable in P1.
- Comparing P4 map pH 5-8 with P16 map pH 5-8, three spots were found to be clearly present in P4 and barely detectable or not detectable in P16, and another seven spots were clearly present in P16 and not in P4.
- Comparing P4 map pH 7-10 with P16 map pH 7-10, two spots were found to be clearly present in P4 and barely detectable or not detectable in P16, and another two spots were clearly present in P16 and barely detectable or not detectable in P4.
- These 44 spots were identified using mass spectrometry analysis. The results are shown in Tables 3-4. Table 3 lists proteins that were identified as particularly interesting targets, due to their known function.
-
TABLE 3 Potentially Relevant Proteins HUMAN HOMOLOG MOUSE GENE GENE # PROTEIN BANK #GI BANK #GI 1. protein BC031593 protein 17512384 (—) 2. protein Ppp3cc 12853166 13937367 3. 14-3-3 PROTEIN TAU homolog 12849349 (—) (14-3-3 PROTEIN THETA) 4. 143B_MOUSE 14-3-3 protein 3065924 (—) beta/alpha 5. 143G_HUMAN 14-3-3 protein 3065928 (—) gamma 6. acid phosphatase 2, lysosomal29150253 4557010 7. Acvr1 protein 15929282 4557243 8. annexin A5; annexin V 6753060 4502107 9. Ca<2+>dependent activator 6753238 34452715 protein for secretion 10. calcium binding protein 2639022 7656952 11. Calnexin 56206506 10716563 12. cathepsin 3 precursor19424144 (—) 13. Cathepsin D 26101892 4503143 14. protein AY100450; WFIKKN- 32451494 (—) like; growth and differentiation factor 15. Cofilin 137194891 5031635 16. Creatine kinase, brain 10946574 (—) 17. Cttn protein 15030315 21707902 18. development- and differentiation- 51827426 (—) enhancing factor 2; PYK2 Chomolog 19. DiGeorge syndrome critical region 29144908 (—) gene 6 product homolog 20. drebrin 1; drebrin E2; drebrin A34328251 18426915 21. fatty acid binding protein 5, 6754450 4503491 epidermal 22. Fbxo9 protein 18044861 53692184 23. fibroblast growth factor 22 12843402 120050 24. FK10_MOUSE FK506 binding 26105984 7706131 protein 10 precursor25. golgi associated, gamma adaptin 22122347 48527954 ear containing, ARF binding protein 1 26. GRP1 (general receptor for 26094386 32171221 phosphoinositides 1)-associated scaffold protein 27. H2-T10 protein 18257363 (—) 28. Hepatoma-derived growth factor 34787412 55960780 29. Inner centromere protein 26353663 51471706 30. integrin beta 2;integrin beta 226353439 4557886 (Cd18); Mac-1 beta; macrophage antigen 31. Male-specific lethal-3 homolog 111545735 5052315 32. Map3k4 protein 37590139 57338496 33. Myristoylated alanine rich protein 6678768 57870608 kinase C substrate 34. NRCA_MOUSE Neuronal cell 26333200 (—) adhesion molecule precursor (Nr- CAM) (NgCAM-related 35. PDZ domain containing homolog 26325701 58533161 36. phosducin homolog 7684610 9943842 37. Profilin 112846944 4826898 38. protein 1200008A14 12835962 (—) 39. protein 2310057D15Rik 12845067 (—) 40. protein 2610111M03Rik 12848227 (—) 41. protein 2700081O15Rik 26083118 (—) 42. protein A830054M12 26090077 (—) 43. protein AI507495 47523976 (—) 44. protein AI663987 51708226 (—) 45. protein AU042671 18044599 (—) 46. protein BC037006 protein 17160955 (—) 47. protein kinase, cAMP dependent 15030299 1346362 regulatory, type I beta 48. protein mKIAA0585 protein 28972291 (—) 49. protein mKIAA0650 12855134 (—) 50. protein mKIAA1565 26349512 (—) 51. protein NUF2R 12963617 12667401 52. protein phosphatase 1, regulatory12832826 (—) (inhibitor) subunit 2 homolog53. Protein phosphatase 2, regulatory37718993 5453952 subunit B (B56), beta isoform 54. protein Prkcsh 14602601 15488917 55. protein putative 40-2-3 protein 26346029 15216162 56. protein Rbbp6 protein 30851332 49522749 57. protein tyrosine phosphatase, 25092609 2842713 receptor type, S 58. Ras-GTPase-activating protein 56800092 54695638 SH3-domain binding protein 59. SH3-domain GRB2 homolog 31560792 55661111 60. S-phase kinase-associated protein 31560543 (—) 1A 61. Tnf receptor-associated factor 36755865 22027620 62. Tnks protein 34980999 (—) 63. Tripartite motif protein 28 59807693 3183179 64. Trk-fused gene 19353070 21361320 65. Ubiquilin 234328236 17426453 66. ubiquitin-like 1 (sentrin) activating 7709986 (—) enzyme E1B; anthracycline- associated 67. Valosin containing protein 30023842 55662798 68. zinc finger protein 120 isoform 231044493 (—) 69. zinc finger protein 462; gene trap 26327260 8036504 insertion site 4-2 70. Zyx protein 32451799 33870614 71. GRP1 (general receptor for 28277382 phosphoinositides 1)-associated scaffold 72. otoferlin [Mus musculus] 51831108 73. Cofilin 1, non-muscle [Mus28374265 musculus] 74. cathepsin 3 precursor [Mus31560606 musculus] 75. Heat shock 70 kD protein 5 31981721 (glucose-regulated protein) [Mus musculus] 76. Acvrl1 protein [Mus musculus] 6752957 77. Tnf receptor-associated factor 36755864 [Mus musculus] 78. integrin alpha 2;integrin alpha 241054730 (Cd49b); VLA-2 receptor, alpha 279. H2-T10 protein [Mus musculus] 51770266 80. fibrillin-1 precursor - mouse 6755774 81. protein tyrosine phosphatase, 33286922 receptor type, S [Mus musculus] 82. transient receptor potential cation 59889895 channel, subfamily M, member 383. calcium channel, voltage- 51712446 dependent, L type, alpha 1S subunit 84. Krt1-15 protein 6680601 85. stress-induced phosphoprotein 1;14389430 stress-inducible protein; IEF SSP 352 86. Hepatoma-derived growth factor 31560690 87. Lmnb1 protein 6754555 88. Myristoylated alanine rich protein 6678767 kinase C substrate 89. phosphoglycerate kinase 30802044 90. acetyl-Coenzyme A 31542049 acetyltransferase 1 - Table 4 is a list of those proteins with unknown function that are differentially expressed during development of the HVS.
-
TABLE 4 Differentially Expressed Unknown Proteins MOUSE GENE BANK SIGNIFICANT Possible function # PROTEIN #GI HOMOLOGY with (by homology) 1. protein 4930477M19 29244200 solute carrier family 22 2. protein XP_358378 38089454 LOC348180 protein 3. protein XP_148779 38082098 unknown 4. protein 4732456N10 29244176 keratin 5 5. protein D630003M21 29244074 KIAA1755 protein homolog 6. protein MGC11770 21450213 alanyl- tRNA synthetase homolog 7. protein 4832416E03 27370264 alanyl-tRNA synthetase homolog 8. protein S25715 284778 unknown protein—mouse 9. protein 4932412H11 27370338 leucine-rich repeat containing protein homolog 10. protein product 26390223 protein disulfide 26390223 isomerase homolog 11. protein product 26351281 Titin homolog 26351281 12. protein product 1333921 crystallin, gamma A 1333921 13. protein product 26354026 tropomyosin 326354026 14. protein product 26338367 unknown 26338367 15. protein product 26329025 unknown 26329025 16. protein product 12852979 PDZ domain 12852979 containing 1 17. protein product 26325560 unknown 26325560 18. protein product 26354901 ankyrin homolog 26354901 19. protein product 26340818 unknown 26340818 20. protein product 26346649 tropomyosin 126346649 21. protein product 26346108 Interferon-induced 26346108 protein 22. protein product 26335149 endothelial progenitor 26335149 cells, angiopoietin homolog 23. protein product 38257031 oogenesin 138257031 24. protein product 26342222 High mobility group 26342222 homolog 25. protein product 26351025 unknown 26351025 26. protein for 38328278 heterogeneous nuclear MGC: 70225 ribonucleoprotein A3 27. protein for 38328232 unknown MGC: 69648 28. protein for 32451767 Snx25 protein MGC: 65613 29. protein for 38328220 septin 11 MGC: 70304 30. protein for 38348540 unknown MGC: 66590 31. protein for 38174349 T-complex protein 10c MGC: 74310 32. protein for 38173718 nestin homolog MGC: 66854 33. cDNA 4930513F16 29789229 IQ calmodulin-binding motif containing protein 34. cDNA 1110021E09 30354152 unknown 35. cDNA 4930578C19 30424860 nucleotide apoptosis triphosphate hydrolases 36. cDNA 6030404K05 30425216 C2H2 zinc-finger at its gene N-terminal region 37. cDNA C730025I08 30425272 RETINOL gene DEHYDROGENASE 38. cDNA 2610019P18 30519939 unknown 39. cDNA C730027J19 30520215 rat hypertension- gene associated homolog 40. cDNA 2610036L13 31127295 cell division cycle angiogenesis associated 5 41. cDNA 5730444A13 31542010 G-protein beta WD-40 apoptosis repeats 42. cDNA 5230400J09 33859785 duf containing peotein, zeta-crystallin 43. cDNA 1500011H22 34784371 unknown 44. cDNA 9030623C06 34980904 keratin 21, type I, cytoskeletal 45. cDNA 6430598A04 34980939 netrin-G1 ligand apoptosis gene NGL-1 46. cDNA 1500031K13 37589970 calcium binding protein 39-like 47. cDNA 3110001E11 38075065 unknown 48. cDNA 1700020H17 38075351 molybdopterin synthase sulfurylase 49. cDNA 4933432B09 38077919 unknown 50. cDNA 1110037F02 38078070 unknown 51. cDNA 5730537H01 38084391 mRNA-decapping enzyme (DCP2) 52. cDNA E330005F07 38089151 microtubule binding gene protein hook3, GTPase 53. cDNA B630009I04 38090459 activating signal cointegrator 1 complex 54. cDNA 9130006A14 38091346 Mus musculus proliferation RasGEF domain and apoptosis family, Cell Division Control Protein 25 55. cDNA F830010I22 38091563 TENSIN homolog 56. cDNA A930040G15 46048307 unknown 57. cDNA 4432411E13 51769098 hyperplastic discs protein, tumor suppressor 58. cDNA C130068M19 59858553 beta WD-40 repeats containing protein
Differential Protein Expression in P1, P4, P8, P16 using IPG Strips pH 3-10 and Phosphostaining - In this experiment, two samples per each post-gestational day were loaded onto nonlinear immobilized pH gradient (IPG) gel strips (7 cm, pH 3-10) and rehydrated overnight with Rehydration/Sample Buffer (Biorad Laboratories, Hercules, Calif.). The same steps were followed for the gel electrophoresis, and then proteins on gel were fixed in 10% acetic acid and 20% methanol overnight. Each of the 8 gels was incubated three times for 10 minutes with 100 mL of dH2O with gentle agitation in order to remove all of the methanol and acetic acid from the gel.
- Then each gel was incubated in the dark in 50 mL of Pro-Q® Diamond phosphoprotein gel stain with gentle agitation for 75-120 minutes (Molecular Probes Laboratories); each gel was destained for two times in 80-100 mL of Destain Solution (Molecular Probes Laboratories) at room temperature, protected from light. Images of each gel were taken with the Image acquisition system Molecular Imager FX Pro Plus. Every gel was then stained for three hours with SYPRO Rubin Protein gel Stain (Biorad Laboratories, Hercules Calif.), and proteins on the gel were fixed twice in 10% acetic acid and 20% methanol for 1 hour. Images of each gel were taken with the Image acquisition system Molecular Imager FX Pro Plus.
- The proprietary fluorescent stain of Pro-Q® Diamond phosphoprotein gel staining (Molecular Probes Laboratories) allows direct in-gel detection of phosphate groups attached to tyrosine, serine or threonine residues. The comparison between the images obtained from P1 and P16 gels stained with the phosphostain showed a different pattern of protein activation. Thirteen protein spot were identified with mass spectroscopy that were present in P1 but not in P16, and nine protein spots present in P16 but not in P1. Proteins identified by this method are listed in Table 5.
-
TABLE 5 PROTEINS WITH ALTERATIONS IN PHOSPHORYLATION HUMAN MOUSE PROTEIN GI # GI# 1810015P09Rik protein 21411262 2610111M03Rik protein 19353142 a disintegrin and metalloprotease domain 4; 27923590 a disintegrin and metallop Albumin 1 19353306 alpha fetoprotein; alpha-foetoprotein 31982513 antibody heavy chain variable region 1518293 B230317C12Rik protein 37994630 Ca2+dependent activator protein for 6753238 secretion Calnexin 25955477 CRAA_MOUSE Alpha crystallin A chain, 117369 major component Cryab protein 14789702 Crybb1 protein 22137737 crystallin, alpha A; lens opacity 18; 30794510 crystallin, alpha 1; alpha-A-cry crystallin, beta A1 20304089 Crystallin, beta A2 31088965 Crystallin, beta B3 37589234 crystallin, gamma B 38049551 Crystallin, gamma C 33990600 Crystallin, gamma D 34784220 Crystallin, gamma F 33991687 Crystallin, gamma S 46854370 or 33989585 47124529 drebrin 1; drebrin E2; drebrin A 34328251 dynein, axonemal, heavy polypeptide 9 38091406 Facl6 protein 16359313 gamma 4-crystallin 51017 Heat shock 70 kD protein 5 (glucose- 29748016 regulated protein) Heat shock protein 1, alpha 28436908 heat shock protein 1, beta; heat shock 6680305 protein, 84 kDa 1; heat shock 90 heat shock protein, 110 kDa 13278232 Hook homolog 1 38197327 HS7C_MOUSE Heat shock cognate 71 kDa 123651 protein Hspcb protein 29612561 hypothetical protein 4732456N10 29244176 IgM heavy chain 1763745 integrin alpha 2; integrin alpha 2 (Cd49b); 6680478 VLA-2 receptor, alpha 2 sub laminin, beta 2; Laminin S 31982223 laminin, gamma 2; nicein, 100 kD; nicein, 19115956 100 kDa Lmnb1 protein 34849832 mannosidase 2, alpha 2; alpha mannosidase 51477716 27777691 IIx; mannosidase, alpha, cla mKIAA0723 protein 37360062 mutS homolog 5 7305281 Myristoylated alanine rich protein kinase C 28302374 substrate Nasp protein 13435642 nuclear autoantigenic sperm protein 13384598 Pleckstrin homology-like domain, family 17512344 A, member 2 prolactin-like protein E; prolactin-like 6679471 protein G protein tyrosine phosphatase, receptor 25092609 type, S PSD3_MOUSE 26S proteasome non-ATPase regulatory 19856169 subunit 3 (26S proteasome reg Rbbp6 protein 30851332 Ribosomal protein S27a 12805285 RIKEN cDNA 0610041L09 21313618 RIKEN cDNA 1500011H22 34784371 RIKEN cDNA 1700028P14 29436989 RIKEN cDNA 3000003F02 27369583 RIKEN cDNA 4432411E13 38077035 RIKEN cDNA 6030404K05 gene 30425216 RIKEN cDNA A030005L19 13386450 RIKEN cDNA D430026P16 gene 28893017 RIKEN cDNA F830010I22 gene 38091563 S25715 hypothetical protein - mouse 284778 (fragment) Serine (or cysteine) proteinase inhibitor, 19343549 clade A, member 1b [Mus muscu Serine (or cysteine) proteinase inhibitor, 38174657 clade A, member 1e [Mus muscu Serpina 1b protein 15277553 similar to 60S ribosomal protein L10 (QM 38079574 protein homolog) [Mus musculu similar to alpha-2-HS-glycoprotein 38080571 homolog - mouse similar to alpha-tubulin 38050521 similar to ATP-binding cassette, sub-family 38049559 A, member 12 isoform b [Mu similar to Crybb1 protein 38074960 similar to Elongation factor 1-alpha 1 (EF- 38090266 1-alpha-1) (Elongation fact similar to heat shock protein hsp90 beta 38096689 similar to hypothetical protein FLJ21665 38074149 similar to K-ALPHA-1 protein 38084290 Similar to neuronal protein 28175466 similar to tubulin Mbeta 1 38075765 similar to tubulin, beta 3 38085389 Solute carrier family 3, member 1 18490867 15488595 S-phase kinase-associated protein 1A 12805297 Synovial sarcoma, X breakpoint 2 21594537 interacting protein Tnks protein 34980999 Tripartite motif protein 28 37231553 trypsinogen 10 2358087 trypsinogen 16 16716569 Tubulin, alpha 2 12805487 Tubulin, alpha 6 20071240 tubulin, beta 21746161 Tubulin, beta 2 33416314 Tubulin, beta 3 21595026 Tubulin, beta 4 32766247 Tubulin, beta 5 13277909 ubiquitin specific protease 9, Y 22507351 chromosome ubiquitin-like 1 (sentrin) activating enzyme 7709986 E1B; anthracycline-associa Unknown (protein for MGC: 69991) 38328337 unnamed protein product 1333921 Valosin containing protein 29144989 vimentin 57471648 31982755 ZIN_MOUSE Striatin 4 (Zinedin) 17367523 1012270B antibody L-V, anti-arsonate GI: 224215 2700081O15Rik protein 37589581 5730509E04Rik protein 20071529 Actin-like 6 29436558 arylalkylamine N-acetyltransferase 6752938 ATPase, H+ transporting, V1 subunit A, 31560731 isoform 1; ATPase, H+ transport beaded filament structural protein 2, 38090061 phakinin Cathepsin D 21450788 CRAA_MOUSE Alpha crystallin A chain, 117369 major component Creatine kinase, brain 15929689 Cryab protein 14789702 Crybb1 protein 22137737 crystallin, alpha A; lens opacity 18; 30794510 crystallin, alpha 1; alpha-A-cry crystallin, beta A1 20304089 Crystallin, beta A2 31088965 Crystallin, beta A4 33989574 crystallin, beta B2; betaB2-crystallin; 6681035 Philly cataract Crystallin, beta B3 37589234 crystallin, gamma B 38049551 Crystallin, gamma C 33990600 Crystallin, gamma D 34784220 Crystallin, gamma F 33991687 crystallin, gamma N 23346485 Crystallin, gamma S 33989585 eukaryotic translation initiation factor 3, 21313620 subunit 5 (epsilon) [Mus m G protein-coupled receptor 106; G protein 15546059 coupled receptor affecting t gamma 4-crystallin 51017 Hnrpk protein 13879427 HS7C_MOUSE Heat shock cognate 71 kDa 123651 protein hypothetical protein 4932412H11 26325921 integrin alpha 2; integrin alpha 2 (Cd49b); 6680478 VLA-2 receptor, alpha 2 sub kinase D-interacting substance of 220 kDa 38049418 Kinesin-like 6 13905108 laminin, beta 2; Laminin S 31982223 Map3k4 protein 37590139 mKIAA1565 protein 37360452 Nitrogen fixation cluster-like 29476869 olfactory receptor GA_x6K02T2PBJ9- 32057602 6773690-6774628 phakinin, CP49 17977856 PSD3_MOUSE 26S proteasome non-ATPase regulatory 19856169 subunit 3 (26S proteasome reg RIKEN cDNA 4833420I20 17390408 RIKEN cDNA 4930578C19 30424860 RIKEN cDNA 4933424A10 gene 28893379 RIKEN cDNA 6030404K05 gene 30425216 RIKEN cDNA 9030623C06 34980904 RIKEN cDNA A030005L19 13386450 RIKEN cDNA A930040G15 19527136 RIKEN cDNA C130068M19 gene 38073604 RIKEN cDNA C730027J19 gene 30520215 RIKEN cDNA F830010I22 gene 38091563 Sema domain, immunoglobulin domain 37046950 (Ig), and GPI membrane anchor, (semap SH3-domain GRB2-like 2 17390906 similar to 14-3-3 protein sigma 38089318 similar to actin, gamma, cytoplasmic 38089775 similar to cytoplasmic beta-actin 38089227 similar to fibrous sheath-interacting protein 2 38074908 similar to integrin alpha 6 38090030 similar to ribosomal protein L31 38085230 solute carrier family 6 (neurotransmitter 19527208 transporter, creatine), memb T-box 1 20891977 trypsinogen 16 16716569 Tubulin, alpha 2 12805487 uncoupling protein 2, mitochondrial 31543920 Unknown (protein for MGC: 66590) 38348540 Unknown (protein for MGC: 69991) 38328337 Unknown (protein for MGC: 74310) 38174349 unnamed protein product 26335149 unnamed protein product 1333921 unnamed protein product 26351281 unnamed protein product 1333921 - The activin receptor-like kinase 1 (ALK1), a TGF-beta1 type I receptor, plays an inhibitory role in angiogenesis and vascular development. Mutations of ALK1 gene are linked to human type II hereditary hemorrhagic telangiectasia. Our purpose was to develop a mouse model to study the differential expression of proteins during the phase of Hyaloid Vascular System (HVS) regression and determine the role of ALK1 in this model.
- Materials and Methods: Thirty-two newborn C57BL/6 mice were sacrificed on post-gestational days 1 (n=20 eyes), 4 (n=20 eyes), 8 (n=12 eyes), and 16 (n=12 eyes). The lens, the Pupillary Membrane (PM), the Tunica Vasculosa Lentis (TVL) and the primary vitreous containing the Vasa Hyaloidea Propria (VHP) were isolated. Proteins were extracted from each specimen, loaded onto nonlinear immobilized pH gradient (IPG) gel strips, and separated by isoelectric points and molecular weights. Protein expression profile at each time point was compared using the Phoretix 2D image analysis software. Proteins from differentially expressed protein spots were isolated and identified using Mass Spectrometry (MS). Immunohistochemistry was performed to determine the expression of ALK1 during the HVS regression phase.
- Results: The generated protein expression maps showed reproducible separation of the protein spots on the 2 Dimension Electrophoresis gels. Up to 1400 proteins spots were detected per gel. Progressive decrease in the number and intensity of the protein spots occurred from P1 to P16, particularly in the area corresponding to pI 4-7 and Mr 30-90 kDa. Twenty protein spots in the P16 gels were not present in the P1 gels.
- MS revealed 39 differentially expressed proteins (PP 16-1 to 39) in the P16 specimens (Table 1). ALK1 was identified as PP16-31 (spot n° 17). The warping of P16 with P1, P4 and P8 showed the presence of this spot only in P4 and P8. Immuno-histochemistry of the cornea, PM, and TVL using anti ALK1 antibody confirmed the presence of ALK1 in the TVL at P4 and P16.
- Conclusion: The synthesis or degradation of one or more proteins, present at P16 (PP16-1 to 39), may be related to the regression of HVS in the mouse. Identification of ALK1 by proteomic analysis and immunohistochemistry in this model suggests that the TGF-beta1 pathway may be involved in this process.
- A time course experiment was designed to examine the changes in protein expression at P1 and P16 throughout the HVS regression process. As this is the first reported application of proteomic analysis on HVS regression, several conditions for tissue selection and preparation were developed and optimized to obtain clean specimens of the lens and vitreous for 2-DE gels.
- Mouse Anterior Tissue Preparation for 2-DE Gels
- For the protein extraction and ALK1 immunolocalization studies, newborn mice were sacrificed on
post-natal days - Two-Dimensional Electrophoresis, Image Analysis and Protein Identification
- Three samples per each post-gestational day were loaded onto nonlinear, immobilized pH gradient (IPG) gel strips (7 cm, pH 3-10), subjected to isoelectric focusing with a programmed voltage gradient at 8,000 V for 5 hours, and rehydrated overnight with rehydration/sample buffer (Biorad Laboratories). IPG strips were equilibrated with buffer containing 6 M urea, 50 mM Tris (pH 8.8), 30% glycerol, 2% SDS (sodium dodecyl sulfate), and 0.001% bromophenol blue containing 2% DTT (dithiothreitol) or 2.5% iodoacetamide. Following equilibration, second-dimension separation was performed on 4-20% SDS-PAGE (SDS-polyacrylamide gel electrophoresis) gels (Biorad Laboratories) with the first-dimension IPG strip embedded in 0.5% agarose at the top. After electrophoresis, the proteins on the gel were fixed in 10% acetic acid and 20% methanol for 1 hour and then stained with SYPRO™ Ruby (Biorad Laboratories). Images of the 2-DE (two-dimensional electrophoresis) gels were captured with Molecular Imager FX Pro Plus multi-imager system and the protein expression profiles at each time point were compared, in triplicate, using the Phoretix 2D image analysis software. Protein spots present in P16 with expression level two- to ten-fold greater than P1 were considered for protein identification. The statistical significance of changes was evaluated using Phoretix 2D software.
- Gel bands (differentially expressed proteins) from 2-DE gels were excised, minced into approximate 1 mm3 pieces with a sterile razor blade of the Xcise technology platform from Proteome system, alkylated, and digested with trypsin (Promega, Madison, Wis.). Peptides were resuspended in 50% acetonitrile with 1% formic acid solution and subjected to nano-LC ESI IT MS/MS analysis. A Surveyor LC pump (Thermo Electron, San Jose, Calif.) with a C18 trapping column (300 μm i.d.×1 mm, Dionex, Sunnyvale, Calif.) and a reversed-phase column 75 μm i.d.×15 cm (Magic C18AQ, 3 μm) was used for nano-LC experiments. An LCQ Deca XP plus ESI mass spectrometer (Thermo Electron, San Jose, Calif.) was used for all the experiments.
- MS/MS data-dependent acquisition followed by database searching with SEQUEST (BioWorks 3.1, Thermo Electron, San Jose, Calif.) allowed protein identification. Fully tryptic peptides were matched with SEQUEST at a delta correlation (ACn) of greater than 0.08 and correlation (Xcorr) greater than 1.9, 2.2, and 3.5 for charged states of +1, +2, and +3, respectively. Peptide mass fingerprints (PMFs) were searched for matches with the virtually generated tryptic protein masses of the NCBInr mouse protein sequence database (available at ncbi.nml.nih.gov). All databases were provided in the public domain by the host institutions. Proteins were noted as differentially expressed if they could not be located at the corresponding position on the 2-DE gel of the other time point.
- Protein expression maps were generated in triplicate for each time point, obtaining a reproducible separation of the protein spots on the 2-DE gels. Up to 1400 protein spots could be detected in each gel with the Phoretix 2D image analysis software (
FIG. 1A ). This software allows the possibility to warp different gel images to improve the quality of the protein spot matching between the gels and allow an easy detection of the differences among the gels. The 2-DE gels were analyzed, and a progressive decrease in the number and intensity of the protein spots from P1 to P16 was observed, particularly of the migrated proteins in the area corresponding to pI 4-7 and Mw30-90 kDa (FIG. 1B-C ). - However, the warping of the 2-D gel images of P1 with P16 revealed the presence of a small number of protein spots for which expression level in P16 was two to ten-fold greater than P1. Twenty protein spots were analyzed using mass spectrometry analysis. Some of these identified proteins displayed slightly different molecular weights and pIs, suggesting the presence of different isoforms or posttranslational modifications. Eighteen differentially expressed proteins were identified; two additional proteins were unclassified and 15 were unknown. ALK1 was identified as
spot # 17. -
TABLE 6 PROTEINS WITH DIFFERENTIAL EXPRESSION AT POST- GESTATIONAL DAY 16HUMAN MOUSE HOMOLOG GENE GENE SPOT # PROTEIN NAME BANK # BANK # 1 RAD50 homolog 6679609 19924130 2 Olfactory receptor 32057602 41200972 GA_x6K02T2PBJ9-6773690- 6774628 3 Cofilin 1, non-muscle28374265 116848 4 Guanine nucleotide-binding 15341782 20357526 protein, β-1 subunit 5 Protein kinase, cAMP dependent 15030299 1346362 regulatory, type I β 6 α enolase (2-phospho-D-glycerate 13637776 119339 hydro-lyase) (non-neural enolase) 7 Cathepsin 3 precursor21450788 30582658 8 Unclassified 9 Knsl7 protein 26095143 Knsl7 10 F-box/LRR-repeat protein 3B (F- 37537783 16306584 box and leucine-rich repeat protein) 11 Enolase 3, β muscle15488630 16554592 12 Albumin 119353306 113576 13 Heat shock cognate 71 kDa 123651 123648 protein 14 Fatty acid binding protein 5, 6754450 4557581 epidermal; keratinocyte lipid binding protein 15 Vimentin 31982755 57471648 16 Tubulin, β 233416314 4507729 17 ALK1 protein 6752957 4557243 18 CRAA_MOUSE α crystallin A 117369 1706112 chain, major component 19 Crystallin, β A4 33989574 4503059 20 Unclassified - To investigate whether ALK1 is expressed in TVL during mouse development, mouse eyes at P1, P4 and P16 were immunostained with anti-ALK1 antibody.
- ALK1 Immunolocalization by Confocal Microscopy
- Mouse eyes harvested at P1, P4, and P16 were embedded in optimal cutting temperature (OCT) compound (Miles, Elkhart, Ind.), frozen in liquid nitrogen, cryostat sectioned, and fixed in acetone for 10 min. After blocking with 1% bovine serum albumin (BSA) (Sigma Chemical Co., St. Louis, Mo.) for 30 min, the sections were incubated for 1 hour with rabbit anti-ALK1 polyclonal antibody (courtesy of Dr. D. A. Marchuck, University of North Carolina) at a concentration of 1:200. A secondary antibody used was fluorescein-conjugated, affinity-purified anti-rabbit IgG antibody (Jackson ImmunoResearch Laboratories, West Grove, Pa.) at a concentration of 1:400. Negative controls were prepared in the same manner, with 1% BSA without primary antibody. Immunostained sections were viewed with a Leica TCS SP2 CLSM confocal laser scanning microscope (Leica, Heidelberg, Germany).
- Results
- The confocal immunohistochemical staining demonstrated that ALK1 is localized in the endothelial cells of the TVL at P1, P4 and P16.
- Naked DNA has been effectively used for the delivery of DNA into mouse corneas. To determine whether ALK1 can inhibit bFGF-induced corneal NV (neovascularization), mouse corneas were injected with naked DNAs of pEF (vector) and pEF-ALK1.
- Plasmid construction and corneal naked DNA injection pYX-Asc-ALK1 cDNA was purchased from ATCC (Manassas, Va.). Plasmids were purified using a Qiagen kit (Valencia, Calif.) according to the manufacturer's instructions. The mouse ALK1 DNA was sequenced and subcloned into pEF expression vector. An
Elongation Factor 1 alpha promoter (pEF; Kim et al., Gene. 1990 Jul. 16; 91(2):217-23) was used to drive the expression of the ALK1 gene. Mouse corneas received a DNA injection of 5 μA of pEF-ALK1 (400 ng/μl) or an injection of 5 μA of vector (400 ng/μl). An antibiotic ophthalmic ointment was used after surgery. - bFGF Pellet Preparation and Corneal Micropocket Assay
- Pellets were made of the slow-release polymer Hydron (polyhydroxyethyl-methacrylate), which contained a combination of 45 ng/pellet of sucralfate (Sigma) and 120 ng/pellet of bFGF (R&D Systems, Minneapolis, Minn.), as previously described by Kenyon et al., Invest Ophthalmol V is Sci 37, 1625-1632 (1996).
- Briefly, a suspension of sterile saline containing the appropriate amount of recombinant bFGF and sucralfate was made and concentrated using a speed-vacuum for 8 minutes. To this suspension, 10 μl of 12% Hydron in ethanol was added. The suspension was then deposited onto a sterilized nylon mesh (LAB Pak, Sefar America, Depew, N.Y.) and embedded between the fibers. The resulting grid of 10 mm×10 mm squares was allowed to dry on a sterile Petri dish for 60 min. The fibers of the mesh were pulled apart under a microscope and, among the approximately 100 pellets produced, 30 to 40 uniformly-sized pellets of 0.4×0.4×0.2 mm were selected for implantation. All procedures were performed under sterile conditions.
- Three days after the naked DNA injections, corneal micropockets were created with a modified von Graefe knife in C57BL/6 mice. Hydron pellets containing 120 ng of human basic FGF were implanted into the corneal pockets.
- Measurement of Corneal Neovascularization
- The corneas were routinely examined and photographed in five positions: en face, superior, inferior, nasal, and temporal with a slit lamp biomicroscope (Nikon FS-2, Tokyo, Japan) on
days - Results
- The ALK1 plus pellet group (
FIG. 2M-P ) showed no evidence of corneal NV at any time point after pellet implantation. The group receiving vector control plus pellets (FIG. 2I-L ) began to develop corneal NV atday 4, and the new vessels continued to grow toward the pellet area atdays days FIG. 2O-P ). This was significantly less than the vector treated mice 3.14 mm2 (p=0.001) and 3.33 mm2 (p=0.001) at 7 and 14 days after bFGF pellet implantation, respectively (FIG. 2K-L ). The no-pellet control groups [ALK1 naked DNA (FIG. 2E-H ) and vector naked DNA (FIG. 2A-D )] did not induce corneal NV. - These results demonstrate that injection of naked pEF-ALK1 DNA blocked bFGF induced corneal NV.
-
- 1. Goumans and Mummery, Int. J. Dev. Biol. 44, 253-265 (2000).
- 2. Goumans et al., Trends. Cardiovasc. Med. 13, 301-307 (2003).
- 3. Pepper, Cytokine Growth Factor. Rev. 8, 21-43 (1997).
- 4. Lamouille et al., Blood 100, 4495-4501 (2002).
- 5. Roman et al., Development 129, 3009-3019 (2002).
- 6. Lebrin et al., Cardiovasc. Res. 65, 599-608 (2005).
- 7. Lebrin et al., EMBO. J. 23, 4018-4028 (2004).
- 8. Gabison et al., Exp. Eye. Res. 78, 579-589 (2004).
- 9. Murthy et al., Invest. Ophthalmol. Vis. Sci. 44, 1837-1842 (2003).
- 10. Chang et al., Curr. Opin. Ophthalmol. 12, 242-249 (2001).
- 11. Dawson et al., Science 285, 245-248 (1999).
- 12. Chang et al., FEBS. Lett. 579, 3601-3606 (2005).
- 13. Urness et al., Nat. Genet. 26, 328-331 (2000).
- It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
Claims (20)
1. A method for identifying a candidate compound for the treatment of a disorder associated with neovascularization, the method comprising:
providing a sample comprising a cell expressing activin receptor-like kinase-1 (ALK1);
contacting the sample with a test compound; and
monitoring expression of ALK1 in the cell,
wherein a test compound that increases the expression of ALK1 is a candidate compound for the treatment of neovascularization.
2. A method for identifying a candidate therapeutic agent for the treatment of a disorder associated with neovascularization, the method comprising:
providing an animal model of the disorder;
administering a candidate compound that increases the expression of activin receptor-like kinase-1 (ALK1) to the animal model; and
monitoring one or more parameters of the disorder in the animal,
wherein a candidate compound that improves a parameter of the disorder is a candidate therapeutic agent for the treatment of a disorder associated with neovascularization.
3. A method of identifying a therapeutic agent for the treatment of a disorder associated with neovascularization, the method comprising:
providing a subject having the disorder;
administering a candidate therapeutic agent that increases the expression of activin receptor-like kinase-1 (ALK1) to the subject; and
monitoring one or more parameters of the disorder in the subject,
wherein a candidate therapeutic agent that improves a parameter of the disorder is a therapeutic agent for the treatment of a disorder associated with neovascularization.
4. The method of claim 1 , wherein the sample comprises cells from a human fetus.
5. The method of claim 1 , wherein the sample comprises cells from a subject having a disorder associated with blood vessel regression.
6. The method of claim 5 , wherein the disorder is retinopathy of prematurity or retrolental fibroplasia.
7. The method of claim 1 , wherein the sample comprises cells from a subject in a stage of development that is associated with vessel regression.
8. The method of claim 7 , wherein the stage is the development of the hyaloid vascular system.
9. The method of claim 3 , wherein the subject is a human subject in a clinical trial.
10. The method of claims 1 , wherein the disorder associated with neovascularization is selected from the group consisting of extraocular and ocular neovascularization.
11. The method of claim 10 , wherein the ocular neovascularization is vitreous, retinal, choroidal, or corneal neovascularization.
12. The method of claim 1 , wherein the disorder associated with neovascularization is cancer.
13. A method for treating a disorder associated with neovascularization in a subject, the method comprising administering a therapeutically effective amount of a therapeutic composition comprising an activin receptor-like kinase-1 (ALK1) polynucleotide or polypeptide, or an active fragment thereof.
14. The method of claim 13 , wherein the composition comprises an ALK1 polypeptide comprising amino acids 22-503 of SEQ ID NO:1, or an ALK1 nucleic acid molecule comprising nucleotides 346-1791 of SEQ ID NO:2.
15. The method of claim 13 , wherein the disorder is an ophthalmological disorder associated with neovascularization.
16. The method of claim 15 , wherein the ophthalmological disorder associated with neovascularization is selected from the group consisting of eye cancer, age-related macular degeneration, retinopathy of prematurity, corneal graft rejection, glaucoma, diabetic retinopathy, wounds, age-related macular degeneration, herpetic and infectious keratitis, ocular ischemia, neovascular glaucoma, corneal, uveal and iris neovascularization, orbital and eyelid tumors, Stevens Johnson Syndrome, ocular cicatricial pemphigoid, and ocular surface diseases.
17. The method of claim 15 , wherein the ophthalmological disorder is associated with corneal, retinal, choroidal, uveal, or iris neovascularization.
18. The method of claim 15 , wherein the administering is topical or parenteral administration into the eye.
19. The method of claim 17 , wherein the administering is by local injection into or near the cornea, retina, vitreous, uvea, orbit, eyelid, conjunctiva, or iris.
20. The method of claim 13 , wherein the disorder is cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/295,834 US20120183523A1 (en) | 2005-02-24 | 2011-11-14 | Methods and Compounds for Promoting Vessel Regression |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65616805P | 2005-02-24 | 2005-02-24 | |
US71999805P | 2005-09-23 | 2005-09-23 | |
US11/363,402 US7897581B2 (en) | 2005-02-24 | 2006-02-24 | Methods and compounds for promoting vessel regression |
US13/007,202 US20110182819A1 (en) | 2005-02-24 | 2011-01-14 | Methods and Compounds for Promoting Vessel Regression |
US13/295,834 US20120183523A1 (en) | 2005-02-24 | 2011-11-14 | Methods and Compounds for Promoting Vessel Regression |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/007,202 Continuation US20110182819A1 (en) | 2005-02-24 | 2011-01-14 | Methods and Compounds for Promoting Vessel Regression |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120183523A1 true US20120183523A1 (en) | 2012-07-19 |
Family
ID=36928105
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/363,402 Expired - Fee Related US7897581B2 (en) | 2005-02-24 | 2006-02-24 | Methods and compounds for promoting vessel regression |
US13/007,202 Abandoned US20110182819A1 (en) | 2005-02-24 | 2011-01-14 | Methods and Compounds for Promoting Vessel Regression |
US13/295,834 Abandoned US20120183523A1 (en) | 2005-02-24 | 2011-11-14 | Methods and Compounds for Promoting Vessel Regression |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/363,402 Expired - Fee Related US7897581B2 (en) | 2005-02-24 | 2006-02-24 | Methods and compounds for promoting vessel regression |
US13/007,202 Abandoned US20110182819A1 (en) | 2005-02-24 | 2011-01-14 | Methods and Compounds for Promoting Vessel Regression |
Country Status (2)
Country | Link |
---|---|
US (3) | US7897581B2 (en) |
WO (1) | WO2006091930A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8642031B2 (en) | 2006-11-02 | 2014-02-04 | Acceleron Pharma, Inc. | Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof |
RU2559532C2 (en) * | 2006-11-02 | 2015-08-10 | Акселерон Фарма, Инк. | Antagonists of alk1 receptor and ligands and their application |
US10059756B2 (en) | 2006-11-02 | 2018-08-28 | Acceleron Pharma Inc. | Compositions comprising ALK1-ECD protein |
WO2009004085A2 (en) * | 2007-07-05 | 2009-01-08 | Novartis Ag | Dsrna for treating viral infection |
JP5685773B2 (en) | 2007-09-07 | 2015-03-18 | ミート アンド ライブストック オーストラリア リミテッド | Drugs with angiogenic and wound healing activity |
CA2723449C (en) | 2008-05-02 | 2020-01-21 | Acceleron Pharma Inc. | Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage |
WO2009139891A2 (en) * | 2008-05-15 | 2009-11-19 | Acceleron Pharma, Inc. | Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7537762B2 (en) * | 2005-09-07 | 2009-05-26 | Amgen Fremont, Inc. | Human monoclonal antibodies to activin receptor-like kinase-1 |
US20090226441A1 (en) * | 2007-11-09 | 2009-09-10 | Minhong Yan | Activin receptor-like kinase-1 compositions and methods of use |
US8455428B2 (en) * | 2006-11-02 | 2013-06-04 | Acceleron Pharma, Inc. | ALK1 receptor and ligand antagonist and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6692925B1 (en) | 1992-11-17 | 2004-02-17 | Ludwig Institute For Cancer Research | Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use |
US20030152926A1 (en) * | 1999-08-11 | 2003-08-14 | Eos Biotechnology, Inc. | Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
-
2006
- 2006-02-24 WO PCT/US2006/006809 patent/WO2006091930A2/en active Application Filing
- 2006-02-24 US US11/363,402 patent/US7897581B2/en not_active Expired - Fee Related
-
2011
- 2011-01-14 US US13/007,202 patent/US20110182819A1/en not_active Abandoned
- 2011-11-14 US US13/295,834 patent/US20120183523A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7537762B2 (en) * | 2005-09-07 | 2009-05-26 | Amgen Fremont, Inc. | Human monoclonal antibodies to activin receptor-like kinase-1 |
US8455428B2 (en) * | 2006-11-02 | 2013-06-04 | Acceleron Pharma, Inc. | ALK1 receptor and ligand antagonist and uses thereof |
US20090226441A1 (en) * | 2007-11-09 | 2009-09-10 | Minhong Yan | Activin receptor-like kinase-1 compositions and methods of use |
Also Published As
Publication number | Publication date |
---|---|
US20060211057A1 (en) | 2006-09-21 |
US20110182819A1 (en) | 2011-07-28 |
WO2006091930A2 (en) | 2006-08-31 |
WO2006091930A3 (en) | 2009-04-16 |
US7897581B2 (en) | 2011-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120183523A1 (en) | Methods and Compounds for Promoting Vessel Regression | |
US8841259B2 (en) | Compositions and methods for treating vascular permeability | |
Segarini et al. | The low density lipoprotein receptor-related protein/α2-macroglobulin receptor is a receptor for connective tissue growth factor | |
JP2006500910A (en) | Means and method for specifically regulating CNS and eye target gene and identification method thereof | |
US20180110837A1 (en) | Methods and assays relating to macrophage differentiation | |
US9765339B2 (en) | FLT3 receptor antagonists for the treatment or the prevention of pain disorders | |
Kliewe et al. | Fibronectin is up‐regulated in podocytes by mechanical stress | |
JPWO2008032876A1 (en) | ER-negative and HER2-negative breast cancer prophylactic or therapeutic agent and screening method thereof | |
US11613753B2 (en) | Methods and pharmaceutical compositions for treating tubulin carboxypeptidases associated diseases | |
US20130333059A1 (en) | Hox compositions and methods | |
WO2006020755A2 (en) | Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics | |
US20130171159A1 (en) | Phosphorylated twist1 and metastasis | |
US20200003788A1 (en) | Exosomal Protein Profiling for Detection of Cardiac Transplant Rejection | |
TAKEMURA et al. | Proto‐oncogene expression in human glomerular diseases | |
KR20130096338A (en) | Screening method using mg53-ube2h interaction for the treatment of type 2 diabetes | |
KR101445930B1 (en) | Marker for diagnosing neovascular retinal disease and its use for therapeutic target | |
RU2797200C1 (en) | Methods and pharmaceutical compositions for the treatment of diseases associated with tubulin carboxypeptidases (tcp) | |
Soundararajan et al. | Proteomic analysis uncovers clusterin-mediated disruption of actin-based contractile machinery in the trabecular meshwork to lower intraocular pressure | |
RU2812207C2 (en) | Methods and pharmaceutical compositions for treatment of diseases associated with tubulin carboxypeptidases (tcp) | |
Reisinger et al. | Cod106, a novel synaptic protein expressed in sensory hair cells of the inner ear and in CNS neurons | |
US8231861B2 (en) | Pancreatitis | |
EP3115784A1 (en) | Polypeptide marker for analysis, diagnosis and therapy of eye-related diseases | |
WO2014043331A2 (en) | Specific phospho-forms of elk-1 as biomarkers and therapeutic targets for cancer | |
WO2006060172A2 (en) | Methods for identifying graft rejection suppressing compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MASSACHUSETTS EYE & EAR INFIRMARY, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AZAR, DIMITRI T.;CHANG, JIN-HONG;ALBE, ELENA;SIGNING DATES FROM 20060504 TO 20060726;REEL/FRAME:028136/0267 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |